Achenbach, S

Genetic background of von Willebrand disease

Adam, E

The predictive value of coagulation parameters for the course of disease in COVID-19 patients

Adenaeuer, A

Conclusion from 50 years of reports on prekallikrein or high-molecular-weight kininogen deficiency

Agarwal, S

Interim 52-Week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A

Ahlin, H

Interim analysis in patients from Germany and Switzerland of the A-MORE study: a 48-month, multi-centre, observational study to evaluate longterm effectiveness of rFVIIIFc on joint health

Ahuja, S

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Akhmedov, A

Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer

Akin, I

Thrombocytopenia in patients with cardiogenic shock treated with extracorporal life support system versus conservative treatment

Al, R Rifai

Intrinsic difference in cellular response between full-length and B-domain deleted FVIII HEK293 secreting cells: implication for gene therapy

Alam, R M

The role of Mitochondrial Calcium Uniporter in platelet signalling

Alberio, L

Emicizumab phamacodynamics assessed by thrombin generation and fibrin clot formation

Evaluating the individual risk of venous thrombo-embolism in patients with liver cirrhosis: Usefulness of in vivo and ex vivo thrombin generation parameters

Sequential combinations of rapid immunoassays for quick recognition of heparin-induced thrombocytopenia

Utility of D-dimers in the diagnostic work-up of heparin-induced thrombocytopenia (HIT)

Identification of key regulators of procoagulant COAT platelet generation by quantitative phosphoproteomic analysis and phosphoflow

The role of Mitochondrial Calcium Uniporter in platelet signalling

In vitro efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis

Albers, S

Establishment of a flow-cytometry panel to analyse binding of FVIII to lymphocyte populations

Albert, T

Influenza infections destabilize established immune tolerance in HemA mice

Albisetti, M

EMIIL - Non-interventional study to investigate the effectiveness of Emicizumab under real-world conditions in pediatric, adolescent, adult and elderly patients with hemophilia A (PwHA) with and without FVIII inhibitors: an interim analysis

Alesci, S R

Survey on the care reality of people with mild hemophilia A and B in Germany - the burden of mild hemophilia

Utility of ACMG classification to support interpretation of molecular genetic test results in patients with FVII deficiency

Von Willebrand-disease_ a patient with a variant of uncertain significance: phenotype like type 1, genotype like type 3

A Survey on anticoagulation in patient with ITP

Aliotta, A

Emicizumab phamacodynamics assessed by thrombin generation and fibrin clot formation

Evaluating the individual risk of venous thrombo-embolism in patients with liver cirrhosis: Usefulness of in vivo and ex vivo thrombin generation parameters

Identification of key regulators of procoagulant COAT platelet generation by quantitative phosphoproteomic analysis and phosphoflow

The role of Mitochondrial Calcium Uniporter in platelet signalling

In vitro efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis

Althaus, K

Severe bleeding in a young patient with mild thrombocytopenia due to a novel mutation in growth factor inhibitor 1B

Inhibition of cold-induced apoptosis of platelet concentrates improves platelet functionality and half-life

Measurement of procoagulant platelets in platelet-rich plasma by flow cytometer for the diagnosis of heparin-induced thrombocytopenia

Anti-PF4 antibodies after SARS-CoV-2 vaccines: long term follow-up

Alvarez Román, T M

Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A

Ambreen, S

Hypercoagulability impairs plaque stability in diabetes-induced atherosclerosis

IRE1α induced senescence promote endothelial barrier dysfunction in diabetes-induced atherosclerosis

Platelet hyperactivation and neutrophil extracellular traps promote thrombo-inflammation and glomerular endothelial dysfunction in diabetic kidney disease

Direct oral anticoagulants cause placental vascular abnormalities and epigenetic reprogramming in placenta and the offspring

Andres, O

Ontogeny of peripheral blood platelet GPIIb/IIIa activation and granule release in preterm and term neonates

Arens, J

Non-clinical pharmacodynamic effects and immunogenicity assessment of prophylactic immune modulation prior to gene therapy dose administration in C57BL/6 mice

Arshad, M

Correlation between von Willebrand Factor and the PI3K/Akt signalling pathway in the control of angiogenesis

Artru, F

Evaluating the individual risk of venous thrombo-embolism in patients with liver cirrhosis: Usefulness of in vivo and ex vivo thrombin generation parameters

Asmis, M L

Recombinant ADAMTS13 treatment in a pregnant patient with hereditary thrombotic thrombocytopenic purpura

Auerswald, G

Efficacy, safety and consumption of plasma-derived von Willebrand factor (VWF)/Factor VIII (FVIII) concentrate with 2.4:1 VWF:FVIII ratio for the treatment of von Willebrand Disease: a systematic review

Ay, C

Relation of FVIII activity levels with global assays of hemostasis in persons with hemophilia A

Vitamin D deficiency in adult patients with primary immune thrombocytopenia (ITP) from the Vienna ITP Biobank

Impaired hemostatic capacity in patients with low von Willebrand factor

Saliva and urine from persons with hemophilia A trigger coagulation bypassing factor VIII

The Post-VTE Functional Status Scale for assessment of functional limitations in patients with venous thromboembolism: construct validity and responsiveness in a prospective cohort study

Characteristics, management, disposition, and outcome of patients with pulmonary embolism in a tertiary care setting

Telomere length is associated with increased risk of cardiovascular events in hemodialysis patients

Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer

Tissue Factor Pathway Inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer

Prevention of coronary and peripheral arterial events in patients with end-stage kidney disease on hemodialysis: prospective results of the VIVALDI study

Bakchoul, T

The impact of Syk-inhibition on 5B9 monoclonal HIT antibody-mediated procoagulant platelet formation

Establishment of an in vitro assay to detect antibody-mediated procoagulant platelet formation on a single cell level in real time

Severe bleeding in a young patient with mild thrombocytopenia due to a novel mutation in growth factor inhibitor 1B

Platelets are pre-activated during thrombocytopenia in a subset of early malaria infections

Establishment of an ex vivo assay to investigate thrombus formation using platelet concentrates

Inhibition of cold-induced apoptosis of platelet concentrates improves platelet functionality and half-life

Measurement of procoagulant platelets in platelet-rich plasma by flow cytometer for the diagnosis of heparin-induced thrombocytopenia

Anti-PF4 antibodies after SARS-CoV-2 vaccines: long term follow-up

Limited concordance of heparin/PF4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study

Barco, S

Conclusion from 50 years of reports on prekallikrein or high-molecular-weight kininogen deficiency

Barelli, S

Utility of D-dimers in the diagnostic work-up of heparin-induced thrombocytopenia (HIT)

Baridon, B

The effect of prophylactic corticosteroid treatment on adeno-associated virus-mediated gene therapy and potential mechanisms of action

Barki, S

The role of Mitochondrial Calcium Uniporter in platelet signalling

Baschin, M

Platelet expression of the transcription factor ETV6 points toward ETV6-related thrombocytopenia and can be detected by immunofluorescence on the blood smear

Bashirians, G

Global seroprevalence of neutralizing antibodies against adeno-associated virus (AAV) serotypes of relevance to gene therapy

Batista Mesquita Sauvage, P A

Emicizumab phamacodynamics assessed by thrombin generation and fibrin clot formation

Bauer, E

Interim analysis in patients from Germany and Switzerland of the A-MORE study: a 48-month, multi-centre, observational study to evaluate longterm effectiveness of rFVIIIFc on joint health

Baumann, S

Thrombocytopenia in patients with cardiogenic shock treated with extracorporal life support system versus conservative treatment

Becher, T

Evaluation of the protein C pathway in critically ill patients with severe COVID-19 as compared to bacterial sepsis

Beck, S

Ontogeny of peripheral blood platelet GPIIb/IIIa activation and granule release in preterm and term neonates

Becker, A K

Agenesis of vena cava inferior (AVCI) and Hypereosinophilic Syndrome (HES): two rare causes of severe thrombosis and its challenging treatment in adolescents

Becker, T

Pain in patients with hereditary bleeding disorders: evaluation of a survey among people affected in Germany

Becker-Gotot, J

Influenza infections destabilize established immune tolerance in HemA mice

Becker-Peters, K

Isolation of vWF-specific antibody fragments from phage-displayed scFv libraries

Beckmann, L

BMS-262084, a FXIa inhibitor, interferes with tumor cell-induced coagulation activation only in tumor cells with low tissue factor (TF) procoagulant activity (PCA)

Expression and release of tumor cell tissue factor triggers recurrent thromboembolism in a patient with endometrial cancer

Beer-Hammer, S

Pharmacological targeting of ACKR3/CXCR7 enhances anticoagulant acylcarnitine levels in platelets and modulates thrombotic response to lipids

Behnes, M

Thrombocytopenia in patients with cardiogenic shock treated with extracorporal life support system versus conservative treatment

Behnisch, W

A snapshot analysis of a prospective, non-interventional study to evaluate real-life prophylactic treatment schedules of factor VIII concentrates

Behringer, W

Characteristics, management, disposition, and outcome of patients with pulmonary embolism in a tertiary care setting

Benítez, O

Patient-reported symptoms to predict intra-articular location of joint bleeds

Berg, P

Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

Bernar, A

Low bone mineral density in hemophiliacs: cell culture experiments to elucidate the role of coagulation factors in bone metabolism

Bertaggia, CalderaraD

Evaluating the individual risk of venous thrombo-embolism in patients with liver cirrhosis: Usefulness of in vivo and ex vivo thrombin generation parameters

Bertaggia, D Calderara

Emicizumab phamacodynamics assessed by thrombin generation and fibrin clot formation

Bertaggia Calderara, D

Identification of key regulators of procoagulant COAT platelet generation by quantitative phosphoproteomic analysis and phosphoflow

Bertaggia-Calderara, D

In vitro efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis

Besford, QA

Understanding the biomolecular corona formation at the nano-bio interface

Beutel, E M

Discriminatory potential of platelet function reference ranges in cardiovascular disease

Beyer-Westendorf, J

Monitoring of argatroban in COVID-19 ICU patients: a prospective study comparing aPTT, point-of-care viscoelastic testing with ECA-test and dTT to LC/MS/MS

Monitoring of unfractionated heparin in critical ill ICU patients: a prospective study comparing aPTT and point-of-care viscoelastic testing with IN /HI ratio to anti-Xa

Periinterventional management of edoxaban in major procedures: results from the DRESDEN NOAC REGISTRY

Treatment of VTE with rivaroxaban in adolescents – long-term results from the prospective Dresden NOAC Registry (NCT01588119)

Bidlingmaier, C

Switching to extended half-life rFVIIIfc: transition of therapy and pharmacokinetics in pediatric patients with severe hemophilia A

PreviouslyuntreatedpatientsinGermany2017 - 2021 – Update 2022

Birschmann, I

Impaired signaling pathways in Glanzmann thrombasthenia platelets

Plasma-derived extracellular vesicles: a look at the preanalytics

Aspirin resistance and higher risk of pump thrombosis in patients with ventricular assist device – a 7-year follow up study

Biswas, A

In-vitro and In-silico characterization of a pathogenic variant in integrin β3 associated with hereditary macrothrombocytopenia

Low resolution cryo-EM maps and AFM analysis combined with alpha fold model of full-length coagulation Factor VIII sheds light on the conformational positioning of the Factor VIII B domain

An improved understanding of native coagulation factor XIII complex structure using cryo-EM

Analyzing secretion-based patterns of the heterozygous species of coagulation Factor XIII B cysteine mutations reported from mild FXIII deficiency using confocal microscopy

Blaesen, S

Aspirin resistance and higher risk of pump thrombosis in patients with ventricular assist device – a 7-year follow up study

Blasberg, J

Aspirin resistance and higher risk of pump thrombosis in patients with ventricular assist device – a 7-year follow up study

Bode, C

Evaluation of the protein C pathway in critically ill patients with severe COVID-19 as compared to bacterial sepsis

Boeckelmann, D

Inherited platelet disorders – a short introduction

Biallelic GNE variants in patients with congenital thrombocytopenia

Bohnert, J

Characteristics, management, disposition, and outcome of patients with pulmonary embolism in a tertiary care setting

Boiti, F

Immune tolerance achievement by low dose factor VIII in PUPs and MTPs under prophylaxis with emicizumab: two case reports

Bokemeyer, C

BMS-262084, a FXIa inhibitor, interferes with tumor cell-induced coagulation activation only in tumor cells with low tissue factor (TF) procoagulant activity (PCA)

Expression and release of tumor cell tissue factor triggers recurrent thromboembolism in a patient with endometrial cancer

Bokies, J

Monitoring of emicizumab in acquired hemophilia A

Bommer, M

Leveraging medical-AI to speed up Cold Agglutinin Disease detection

Bonanad, S Boix

Patient-reported symptoms to predict intra-articular location of joint bleeds

Bonner, A

Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec (CSL222) vs. extended half-life Factor IX therapies for severe or moderately severe hemophilia B

Bonzo, D

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Böttcher, L

Establishment of an in vitro assay to detect antibody-mediated procoagulant platelet formation on a single cell level in real time

Bouwman, T

The effect of prophylactic corticosteroid treatment on adeno-associated virus-mediated gene therapy and potential mechanisms of action

Bouzabia, B

Pharmacological targeting of ACKR3/CXCR7 enhances anticoagulant acylcarnitine levels in platelets and modulates thrombotic response to lipids

Boyer, R

Non-clinical pharmacodynamic effects and immunogenicity assessment of prophylactic immune modulation prior to gene therapy dose administration in C57BL/6 mice

Bradacova, P

Can APC inhibition by lupus anticoagulants indicate antibody thrombogenicity?

Brandsma, E

Exploring red blood cells as a novel tolerogenic approach for Factor VIII inhibitors employing immuno-dominant FVIII derived peptides presented on MHC class II

Brehm, A M

Correlation between von Willebrand Factor and the PI3K/Akt signalling pathway in the control of angiogenesis

Analysis of single nucleotide polymorphisms in the C4 domain of vWF reveals the novel gain-of-function variant p.Ser2564Arg

Broto, M

Developing an assay to distinguish between HIT and VITT antibodies

Brühl, M

Insights in pain processing of affected versus non-affected structures

Buch, G

Discriminatory potential of platelet function reference ranges in cardiovascular disease

Budde, U

Diagnostic challenges of Thrombotic Thrombocytopenic Purpura: Results from a cohort of 3,100 individual patients in a time period of 21 months

Bullens, S

The effect of prophylactic corticosteroid treatment on adeno-associated virus-mediated gene therapy and potential mechanisms of action

Bunting, S

The effect of prophylactic corticosteroid treatment on adeno-associated virus-mediated gene therapy and potential mechanisms of action

Buri, M

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

Bystrická, L

Interim analysis in patients from Germany and Switzerland of the A-MORE study: a 48-month, multi-centre, observational study to evaluate longterm effectiveness of rFVIIIFc on joint health

Cairo, A

The effect of DNA methylation on inhibitor development in haemophilia A patients treated with FVIII concentrates

Calderara, DB

The role of Mitochondrial Calcium Uniporter in platelet signalling

Canaro, M Hirnyk

Patient-reported symptoms to predict intra-articular location of joint bleeds

Carcao, M

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Casini, A

Emicizumab phamacodynamics assessed by thrombin generation and fibrin clot formation

Castaman, G

Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B

Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Catalani, O

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Cebo, M

Pharmacological targeting of ACKR3/CXCR7 enhances anticoagulant acylcarnitine levels in platelets and modulates thrombotic response to lipids

Chambost, H

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Chand, H

The effect of DNA methylation on inhibitor development in haemophilia A patients treated with FVIII concentrates

Chang, T

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

Chasakova, K

Markers of coagulopathy in multiple myeloma

Chatterjee, M

Pharmacological targeting of ACKR3/CXCR7 enhances anticoagulant acylcarnitine levels in platelets and modulates thrombotic response to lipids

Chavele, K-M

Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1

Chawla, P

Establishment and specification analysis of LSEC-like endothelial cells for the detection of endogenous FVIII

Chhabra, A

Global seroprevalence of neutralizing antibodies against adeno-associated virus (AAV) serotypes of relevance to gene therapy

Chowdary, P

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Chowdhury, S

Air pollution impacts on in-hospital case-fatality rate of ischemic stroke patients

Cibis, L C

The predictive value of coagulation parameters for the course of disease in COVID-19 patients

Collins, P

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

Cooper, D

Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B

Coppens, M

Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Cuntz, F

Single center experience with emicizumab for primary bleeding prophylaxis in children < 2 years of age with severe hemophilia A

Current diagnostic and therapeutic standard of iliac vein compression syndrome (May-Thurner syndrome) in children, adolescents and young adults. A survey among national thrombosis experts

Curtin, J

Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B

da Fonseca, C Pereira

Global seroprevalence of neutralizing antibodies against adeno-associated virus (AAV) serotypes of relevance to gene therapy

Dahlen, B

Discriminatory potential of platelet function reference ranges in cardiovascular disease

Platelet responsiveness in the post-acute phase of pulmonary embolism

Danckwardt, S

Tumour derived prothrombin interacts with tumour PAR1 receptors

Alternative polyadenylation regulates VEGF-coreceptor NRP1

Daventure, V

Induction of neonatal tolerance to therapeutic FVIII in hemophilia A

Davis, J

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Day, J

Interim 52-Week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A

Dayo, J

Randomized-controlled cross-over pilot study on the effectiveness of manual lymphatic drainage in patients with hemophilic arthropathy

de, L Waele

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

de, S Meyer

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

De, L Witte

At the forefront of the introduction of gene therapy in hemophilia A and B: Design and implementation of an innovative software platform ("smart medication Gene") for gene therapy

Degreif, A

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

de Hart, G

Interim 52-Week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A

Dekimpe, C

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

Delignant, S

Induction of neonatal tolerance to therapeutic FVIII in hemophilia A

Dempfle, E C

Utility of ACMG classification to support interpretation of molecular genetic test results in patients with FVII deficiency

Detering, C

Possible immune reaction to COVID-19 vaccination - a case report

Dhalluin, C

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

Dietze, A

Monitoring of unfractionated heparin in critical ill ICU patients: a prospective study comparing aPTT and point-of-care viscoelastic testing with IN /HI ratio to anti-Xa

Dimitrov, D J

Induction of neonatal tolerance to therapeutic FVIII in hemophilia A

Dittrich, K

Pharmacological targeting of ACKR3/CXCR7 enhances anticoagulant acylcarnitine levels in platelets and modulates thrombotic response to lipids

Dittrich, M

Impaired signaling pathways in Glanzmann thrombasthenia platelets

Dixer, B

Vitamin D deficiency in adult patients with primary immune thrombocytopenia (ITP) from the Vienna ITP Biobank

Dobosz, P

Developing an assay to distinguish between HIT and VITT antibodies

Dolmetsch, R

Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B

Domingo Fernandez, D

Heme-triggered effects on blood coagulation: a bioinformatics approach based on experimental data

Döring, M

HSCT in a newborn suffering from SCID and severe haemophilia A

Döring, Y

Gut microbiota promotes arterial thrombus formation in hyperlipidemic Ldlr-/- mouse model

Drayss, M

Ontogeny of peripheral blood platelet GPIIb/IIIa activation and granule release in preterm and term neonates

Dreier, L

Long term observation of therapy and outcome in acquired hemophilia A

Duerschmied, D

Thrombocytopenia in patients with cardiogenic shock treated with extracorporal life support system versus conservative treatment

Dunn, A

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Durual, S

Emicizumab phamacodynamics assessed by thrombin generation and fibrin clot formation

D’Avino, N

Leveraging medical-AI to speed up Cold Agglutinin Disease detection

d’Oiron, R

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Eberl, W

Current diagnostic and therapeutic standard of iliac vein compression syndrome (May-Thurner syndrome) in children, adolescents and young adults. A survey among national thrombosis experts

Eichler, H

Efficacy of emicizumab prophylaxis in patients with severe hemophilia A in Germany: Follow-up evaluation of real-life-data documented by smart medication eDiary

HEM-POWR study: Subgroup analysis evaluating the real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Germany

Blood-induced inflammation in hemophilia

Eid, E

Therapeutic interventions and use of point of care DOAC Dipstick test in stroke patients: an interim analysis of a prospective cohort study

El, S Hazzouri

Intrinsic difference in cellular response between full-length and B-domain deleted FVIII HEK293 secreting cells: implication for gene therapy

Eladly, F

Investigation Of endometriosis symptoms and tumor marker CA 125 in patients With hereditary Von Willebrand disease

Elmaarri, O

The effects of single and combined knockouts of GABARAPs proteins family on FVIII secretion

El-Maarri, O

Intrinsic difference in cellular response between full-length and B-domain deleted FVIII HEK293 secreting cells: implication for gene therapy

Elwakiel, A

Hypercoagulability impairs plaque stability in diabetes-induced atherosclerosis

Engelmaier, A

Sensitive and unambiguous measurement of the activated contact activation factor XII

A sensitive and selective method for the measurement of activated factor X based on complex formation with tissue factor pathway inhibitor

Engelmann, B

Participation of T helper cell-mediated negative regulation of coagulation in human arterial thrombosis

Englisch, C

Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer

Tissue Factor Pathway Inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer

Erlacher, M

Biallelic GNE variants in patients with congenital thrombocytopenia

Escuriola, C

A snapshot analysis of a prospective, non-interventional study to evaluate real-life prophylactic treatment schedules of factor VIII concentrates

Escuriola Ettingshausen, C

PreviouslyuntreatedpatientsinGermany2017 - 2021 – Update 2022

Escuriola-Ettingshausen, C

Efficacy of emicizumab prophylaxis in patients with severe hemophilia A in Germany: Follow-up evaluation of real-life-data documented by smart medication eDiary

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

EMIIL - Non-interventional study to investigate the effectiveness of Emicizumab under real-world conditions in pediatric, adolescent, adult and elderly patients with hemophilia A (PwHA) with and without FVIII inhibitors: an interim analysis

Esmon, N

Endothelial protein C receptor signaling regulates myeloid-biased hematopoiesis under stress and in aging

Esmon, T C

Endothelial protein C receptor signaling regulates myeloid-biased hematopoiesis under stress and in aging

Espinola-Klein, C

Mansoor’s self-report tool for cardiovascular risk assessment predicts adverse in-hospital events in patients with pulmonary embolism

Platelet responsiveness in the post-acute phase of pulmonary embolism

Esteban, O

Developing an assay to distinguish between HIT and VITT antibodies

Ezigbo, D E

Conclusion from 50 years of reports on prekallikrein or high-molecular-weight kininogen deficiency

Falter, T

Conclusion from 50 years of reports on prekallikrein or high-molecular-weight kininogen deficiency

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

Fatima, S

Hypercoagulability impairs plaque stability in diabetes-induced atherosclerosis

IRE1α induced senescence promote endothelial barrier dysfunction in diabetes-induced atherosclerosis

Platelet hyperactivation and neutrophil extracellular traps promote thrombo-inflammation and glomerular endothelial dysfunction in diabetic kidney disease

Direct oral anticoagulants cause placental vascular abnormalities and epigenetic reprogramming in placenta and the offspring

Feddern, J

A snapshot analysis of a prospective, non-interventional study to evaluate real-life prophylactic treatment schedules of factor VIII concentrates

Felbor, U

A novel, homozygous mutation in GFI1B causing inherited thrombocytopenia with Glanzmann-like platelet dysfunction

Fenel, D

Low resolution cryo-EM maps and AFM analysis combined with alpha fold model of full-length coagulation Factor VIII sheds light on the conformational positioning of the Factor VIII B domain

Fiedler, A S

Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

Fijnvandraat, K

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

Exploring red blood cells as a novel tolerogenic approach for Factor VIII inhibitors employing immuno-dominant FVIII derived peptides presented on MHC class II

Filip, J

HEM-POWR study: Subgroup analysis evaluating the real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Germany

Fillitz, M

Vitamin D deficiency in adult patients with primary immune thrombocytopenia (ITP) from the Vienna ITP Biobank

Finger, J

Investigation Of endometriosis symptoms and tumor marker CA 125 in patients With hereditary Von Willebrand disease

Fischer, R

Efficacy of emicizumab prophylaxis in patients with severe hemophilia A in Germany: Follow-up evaluation of real-life-data documented by smart medication eDiary

Fleck, E

Genetic background of von Willebrand disease

Flieder, T

Impaired signaling pathways in Glanzmann thrombasthenia platelets

Plasma-derived extracellular vesicles: a look at the preanalytics

Aspirin resistance and higher risk of pump thrombosis in patients with ventricular assist device – a 7-year follow up study

Fong, S

The effect of prophylactic corticosteroid treatment on adeno-associated virus-mediated gene therapy and potential mechanisms of action

Fontana, P

EMIIL - Non-interventional study to investigate the effectiveness of Emicizumab under real-world conditions in pediatric, adolescent, adult and elderly patients with hemophilia A (PwHA) with and without FVIII inhibitors: an interim analysis

Fraga, M

Evaluating the individual risk of venous thrombo-embolism in patients with liver cirrhosis: Usefulness of in vivo and ex vivo thrombin generation parameters

In vitro efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis

Freson, K

Aggregates of non-muscle myosin IIA in the erythrocytes associate with GATA1-related thrombocytopenia

Freyer, C

Assessment of platelet abnormalities in patients with DiGeorge Syndrome by immunofluorescence microscopy on the blood smear

Platelet expression of the transcription factor ETV6 points toward ETV6-related thrombocytopenia and can be detected by immunofluorescence on the blood smear

Aggregates of non-muscle myosin IIA in the erythrocytes associate with GATA1-related thrombocytopenia

Friedman, KD

Neonatal exchange transfusion: hereditary thrombotic thrombocytopenic purpura (hTTP) should be in the differential diagnosis

Friedrich, C

Patient-reported symptoms to predict intra-articular location of joint bleeds

Fu, X

Pharmacological targeting of ACKR3/CXCR7 enhances anticoagulant acylcarnitine levels in platelets and modulates thrombotic response to lipids

Fuhrmann, J

Developing an assay to distinguish between HIT and VITT antibodies

Fumoso, F

Assessment of platelet abnormalities in patients with DiGeorge Syndrome by immunofluorescence microscopy on the blood smear

Funk, B M

Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

Gall, H

Factor V Leiden paradox in Factor V Leiden homozygotes – a retrospective cohort study

Gallistl, S

Developing an assay to determine the individual osteoclastogenic potential of patients with coagulation disorders in-vitro: challenges and pitfalls

Ganslmeier, M

The beauty of real-world data. EHL factor concentrates contribute to declining annual bleed rates

Ganter, MT

Recombinant ADAMTS13 treatment in a pregnant patient with hereditary thrombotic thrombocytopenic purpura

Garcia, LJ Frade

Patient-reported symptoms to predict intra-articular location of joint bleeds

Gebauer, B

Current diagnostic and therapeutic standard of iliac vein compression syndrome (May-Thurner syndrome) in children, adolescents and young adults. A survey among national thrombosis experts

Gebetsberger, J

Low bone mineral density in hemophiliacs: cell culture experiments to elucidate the role of coagulation factors in bone metabolism

Gebhart, J

Vitamin D deficiency in adult patients with primary immune thrombocytopenia (ITP) from the Vienna ITP Biobank

Impaired hemostatic capacity in patients with low von Willebrand factor

Geisen, C

Genetic background of von Willebrand disease

Treatment of a patient with von Willebrand disease type 2B and severe thrombocytopenia due to mutation p.V1316M with thrombopoietin receptor agonist Avatrombopag

Geisler, T

Pharmacological targeting of ACKR3/CXCR7 enhances anticoagulant acylcarnitine levels in platelets and modulates thrombotic response to lipids

George, JN

Neonatal exchange transfusion: hereditary thrombotic thrombocytopenic purpura (hTTP) should be in the differential diagnosis

Georgiev, H

Biallelic GNE variants in patients with congenital thrombocytopenia

Gerber, B

Limited concordance of heparin/PF4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study

Gerdes, C

Platelet responsiveness in the post-acute phase of pulmonary embolism

Geyer, M

An improved understanding of native coagulation factor XIII complex structure using cryo-EM

Giabbani, E

Biobanking for testing hemostasis: Long-term stability of citrated plasma samples

Giebel, B

Plasma-derived extracellular vesicles: a look at the preanalytics

Goldmann, G

Patient-reported symptoms to predict intra-articular location of joint bleeds

Preanalytical quenching of FVIII using FVIII-inhibitors improves the specificity of functional emicizumab testing

Digital joint discovery tool to support hemophilia patient education

Pain in patients with hereditary bleeding disorders: evaluation of a survey among people affected in Germany

Gomez, J F

Emicizumab phamacodynamics assessed by thrombin generation and fibrin clot formation

Sequential combinations of rapid immunoassays for quick recognition of heparin-induced thrombocytopenia

Utility of D-dimers in the diagnostic work-up of heparin-induced thrombocytopenia (HIT)

Gomez, K

Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec (CSL222) vs. extended half-life Factor IX therapies for severe or moderately severe hemophilia B

Gómez, MDC del Castillo

Patient-reported symptoms to predict intra-articular location of joint bleeds

Goodyer, M

Utility of D-dimers in the diagnostic work-up of heparin-induced thrombocytopenia (HIT)

Graf, C

Endothelial protein C receptor signaling regulates myeloid-biased hematopoiesis under stress and in aging

Immune modulation by the endothelial protein C receptor (EPCR) in cancer progression

Graf, L

Interim analysis in patients from Germany and Switzerland of the A-MORE study: a 48-month, multi-centre, observational study to evaluate longterm effectiveness of rFVIIIFc on joint health

Limited concordance of heparin/PF4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study

Grandoni, F

Sequential combinations of rapid immunoassays for quick recognition of heparin-induced thrombocytopenia

Gray, K

Leveraging medical-AI to speed up Cold Agglutinin Disease detection

Greinacher, A

Assessment of platelet abnormalities in patients with DiGeorge Syndrome by immunofluorescence microscopy on the blood smear

Platelet expression of the transcription factor ETV6 points toward ETV6-related thrombocytopenia and can be detected by immunofluorescence on the blood smear

A novel, homozygous mutation in GFI1B causing inherited thrombocytopenia with Glanzmann-like platelet dysfunction

Aggregates of non-muscle myosin IIA in the erythrocytes associate with GATA1-related thrombocytopenia

Platelet GPIIbIIIa enriched membrane protrusions (Tether) in healthy and diseased individuals

Role of Neuraminidase A of S. pneumoniae on platelet-bacteria-interaction

The impact of enhanced platelet turnover on platelet reactivity in healthy humans

Developing an assay to distinguish between HIT and VITT antibodies

Subsequent vaccinations in VITT patients other than SARS-CoV2 vaccination

Limited concordance of heparin/PF4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study

Greiner, A

Current diagnostic and therapeutic standard of iliac vein compression syndrome (May-Thurner syndrome) in children, adolescents and young adults. A survey among national thrombosis experts

Griffin, H J

Endothelial protein C receptor signaling regulates myeloid-biased hematopoiesis under stress and in aging

Grunz, K

Endothelial protein C receptor signaling regulates myeloid-biased hematopoiesis under stress and in aging

Güldner, A

Monitoring of argatroban in COVID-19 ICU patients: a prospective study comparing aPTT, point-of-care viscoelastic testing with ECA-test and dTT to LC/MS/MS

Monitoring of unfractionated heparin in critical ill ICU patients: a prospective study comparing aPTT and point-of-care viscoelastic testing with IN /HI ratio to anti-Xa

Gummert, J

Aspirin resistance and higher risk of pump thrombosis in patients with ventricular assist device – a 7-year follow up study

Günther, M

The phenotypic and genetic assessment of hereditary antithrombin deficiency in 215 patients from the Rhein-Ruhr area in Germany

Gupta, A

Hypercoagulability impairs plaque stability in diabetes-induced atherosclerosis

IRE1α induced senescence promote endothelial barrier dysfunction in diabetes-induced atherosclerosis

Platelet hyperactivation and neutrophil extracellular traps promote thrombo-inflammation and glomerular endothelial dysfunction in diabetic kidney disease

Direct oral anticoagulants cause placental vascular abnormalities and epigenetic reprogramming in placenta and the offspring

Gupta, S

Interim 52-Week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A

Non-clinical pharmacodynamic effects and immunogenicity assessment of prophylactic immune modulation prior to gene therapy dose administration in C57BL/6 mice

Gur-Cohen, S

Endothelial protein C receptor signaling regulates myeloid-biased hematopoiesis under stress and in aging

Gut, R

Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Gutensohn, K

Possible immune reaction to COVID-19 vaccination - a case report

Haag, M

Pharmacological targeting of ACKR3/CXCR7 enhances anticoagulant acylcarnitine levels in platelets and modulates thrombotic response to lipids

Haegele, F

Blood-induced inflammation in hemophilia

Hafer, L

Assessment of health status, quality of life and physiCAL functIoninG of refUgee hemophiLia patients from UkrAine (CALIGULA Study)

Hagedorn, N

Single center experience with emicizumab for primary bleeding prophylaxis in children < 2 years of age with severe hemophilia A

Current diagnostic and therapeutic standard of iliac vein compression syndrome (May-Thurner syndrome) in children, adolescents and young adults. A survey among national thrombosis experts

Hagelukean, G

An improved understanding of native coagulation factor XIII complex structure using cryo-EM

Hahad, O

Air pollution impacts on in-hospital case-fatality rate of ischemic stroke patients

Hahn, D

Polymer anchors with responsive heparin release for the anticoagulant decoration of hemodialysis membranes

Haidl, H

Developing an assay to determine the individual osteoclastogenic potential of patients with coagulation disorders in-vitro: challenges and pitfalls

Halimeh, S

Survey on the care reality of people with mild hemophilia A and B in Germany - the burden of mild hemophilia

Patient-reported symptoms to predict intra-articular location of joint bleeds

A single-centre approach for a safe and individualized tolerization phase for the treatment of PUPs with severe haemophilia A

A snapshot analysis of a prospective, non-interventional study to evaluate real-life prophylactic treatment schedules of factor VIII concentrates

HEM-POWR study: Subgroup analysis evaluating the real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Germany

Impaired signaling pathways in Glanzmann thrombasthenia platelets

Pain in patients with hereditary bleeding disorders: evaluation of a survey among people affected in Germany

Assessment of health status, quality of life and physiCAL functIoninG of refUgee hemophiLia patients from UkrAine (CALIGULA Study)

The phenotypic and genetic assessment of hereditary antithrombin deficiency in 215 patients from the Rhein-Ruhr area in Germany

Hamedani, NS

Investigating the interaction of circulating von Willebrand factor with polymorphonuclear leukocytes ex vivo

Hammer, S

Severe bleeding in a young patient with mild thrombocytopenia due to a novel mutation in growth factor inhibitor 1B

Measurement of procoagulant platelets in platelet-rich plasma by flow cytometer for the diagnosis of heparin-induced thrombocytopenia

Hammerer-Lercher, A

Limited concordance of heparin/PF4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study

Hammerschmidt, S

Role of Neuraminidase A of S. pneumoniae on platelet-bacteria-interaction

Handtke, S

Role of Neuraminidase A of S. pneumoniae on platelet-bacteria-interaction

The impact of enhanced platelet turnover on platelet reactivity in healthy humans

Handyside, B

The effect of prophylactic corticosteroid treatment on adeno-associated virus-mediated gene therapy and potential mechanisms of action

Non-clinical pharmacodynamic effects and immunogenicity assessment of prophylactic immune modulation prior to gene therapy dose administration in C57BL/6 mice

Harenberg, J

Therapeutic interventions and use of point of care DOAC Dipstick test in stroke patients: an interim analysis of a prospective cohort study

Use of DOAC Dipstick point-of-care testing in patients with acute stroke and transient ischemic attack

Härtel, C

Ontogeny of peripheral blood platelet GPIIb/IIIa activation and granule release in preterm and term neonates

Hartleb, S

Alternative polyadenylation regulates VEGF-coreceptor NRP1

Haslacher, H

Impaired hemostatic capacity in patients with low von Willebrand factor

Hassan, S

The effect of DNA methylation on inhibitor development in haemophilia A patients treated with FVIII concentrates

Hauptmann, S

Recombinant ADAMTS13 treatment in a pregnant patient with hereditary thrombotic thrombocytopenic purpura

Häuser, F

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

Hecking, C

Utility of ACMG classification to support interpretation of molecular genetic test results in patients with FVII deficiency

Von Willebrand-disease_ a patient with a variant of uncertain significance: phenotype like type 1, genotype like type 3

Heemskerk, JWM

A hierarchical network of Src, Syk, Btk and PKC controls GPVI-dependent human platelet activation

Heidel, F

Platelet GPIIbIIIa enriched membrane protrusions (Tether) in healthy and diseased individuals

Heidersdorf, B

EMIIL - Non-interventional study to investigate the effectiveness of Emicizumab under real-world conditions in pediatric, adolescent, adult and elderly patients with hemophilia A (PwHA) with and without FVIII inhibitors: an interim analysis

Heitmeier, S

Platelet responsiveness in the post-acute phase of pulmonary embolism

Heller, C

Patient-reported symptoms to predict intra-articular location of joint bleeds

Helmecke, T

Polymer anchors with responsive heparin release for the anticoagulant decoration of hemodialysis membranes

Henkes, H

Anti-PF4 antibodies after SARS-CoV-2 vaccines: long term follow-up

Henny, C

Biobanking for testing hemostasis: Long-term stability of citrated plasma samples

Henschkowski-Serra, J

Recombinant ADAMTS13 treatment in a pregnant patient with hereditary thrombotic thrombocytopenic purpura

Henshaw, J

Interim 52-Week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A

Henstock, V P

Global seroprevalence of neutralizing antibodies against adeno-associated virus (AAV) serotypes of relevance to gene therapy

Herbst, K

Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A

Herepath, M

Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec (CSL222) vs. extended half-life Factor IX therapies for severe or moderately severe hemophilia B

Hermans, C

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Hetjens, S

Therapeutic interventions and use of point of care DOAC Dipstick test in stroke patients: an interim analysis of a prospective cohort study

Use of DOAC Dipstick point-of-care testing in patients with acute stroke and transient ischemic attack

Heubisch, CL M

Monitoring of emicizumab in acquired hemophilia A

Heubner, L

Monitoring of argatroban in COVID-19 ICU patients: a prospective study comparing aPTT, point-of-care viscoelastic testing with ECA-test and dTT to LC/MS/MS

Monitoring of unfractionated heparin in critical ill ICU patients: a prospective study comparing aPTT and point-of-care viscoelastic testing with IN /HI ratio to anti-Xa

Heyder, L

Efficacy, safety and consumption of plasma-derived von Willebrand factor (VWF)/Factor VIII (FVIII) concentrate with 2.4:1 VWF:FVIII ratio for the treatment of von Willebrand Disease: a systematic review

Hilberg, T

Insights in pain processing of affected versus non-affected structures

Structural alteration and impact on pain perception in patients with haemophilia

Hluší, A

Can APC inhibition by lupus anticoagulants indicate antibody thrombogenicity?

Hobohm, L

Air pollution impacts on in-hospital case-fatality rate of ischemic stroke patients

Mansoor’s self-report tool for cardiovascular risk assessment predicts adverse in-hospital events in patients with pulmonary embolism

Hofer, S

Impaired hemostatic capacity in patients with low von Willebrand factor

Hoffmann, U

Thrombocytopenia in patients with cardiogenic shock treated with extracorporal life support system versus conservative treatment

Hoffmeister, K

Biallelic GNE variants in patients with congenital thrombocytopenia

Hofmann, U

Pharmacological targeting of ACKR3/CXCR7 enhances anticoagulant acylcarnitine levels in platelets and modulates thrombotic response to lipids

Hohbein, A

Impaired signaling pathways in Glanzmann thrombasthenia platelets

Aspirin resistance and higher risk of pump thrombosis in patients with ventricular assist device – a 7-year follow up study

Hohensinner, P

Telomere length is associated with increased risk of cardiovascular events in hemodialysis patients

Hollenbach, S

Assessment of platelet abnormalities in patients with DiGeorge Syndrome by immunofluorescence microscopy on the blood smear

Holstein, K

Survey on the care reality of people with mild hemophilia A and B in Germany - the burden of mild hemophilia

Efficacy of emicizumab prophylaxis in patients with severe hemophilia A in Germany: Follow-up evaluation of real-life-data documented by smart medication eDiary

HEM-POWR study: Subgroup analysis evaluating the real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Germany

Expression and release of tumor cell tissue factor triggers recurrent thromboembolism in a patient with endometrial cancer

Holzer, U

HSCT in a newborn suffering from SCID and severe haemophilia A

Holzhauer, S

Real-world experience on the use of rIX-FP in patients with hemophilia B: interim results from a prospective, non-interventional study in Germany

Interim analysis in patients from Germany and Switzerland of the A-MORE study: a 48-month, multi-centre, observational study to evaluate longterm effectiveness of rFVIIIFc on joint health

Assessment of platelet abnormalities in patients with DiGeorge Syndrome by immunofluorescence microscopy on the blood smear

Platelet expression of the transcription factor ETV6 points toward ETV6-related thrombocytopenia and can be detected by immunofluorescence on the blood smear

Single center experience with emicizumab for primary bleeding prophylaxis in children < 2 years of age with severe hemophilia A

Current diagnostic and therapeutic standard of iliac vein compression syndrome (May-Thurner syndrome) in children, adolescents and young adults. A survey among national thrombosis experts

Hopp, M-T

Hemolysis-derived heme interacts with components of the blood coagulation system

Heme-triggered effects on blood coagulation: a bioinformatics approach based on experimental data

Hoyer, C

Use of DOAC Dipstick point-of-care testing in patients with acute stroke and transient ischemic attack

Hrachovinova, I

Neonatal exchange transfusion: hereditary thrombotic thrombocytopenic purpura (hTTP) should be in the differential diagnosis

Hu, Y

Saliva and urine from persons with hemophilia A trigger coagulation bypassing factor VIII

Hukauf, M

Patient-reported symptoms to predict intra-articular location of joint bleeds

Huseynov, A

Thrombocytopenia in patients with cardiogenic shock treated with extracorporal life support system versus conservative treatment

Ibrahim, M

The effects of single and combined knockouts of GABARAPs proteins family on FVIII secretion

Intrinsic difference in cellular response between full-length and B-domain deleted FVIII HEK293 secreting cells: implication for gene therapy

Icheva, V

HSCT in a newborn suffering from SCID and severe haemophilia A

Imhof, D

Hemolysis-derived heme interacts with components of the blood coagulation system

Heme-triggered effects on blood coagulation: a bioinformatics approach based on experimental data

Isermann, B

Hypercoagulability impairs plaque stability in diabetes-induced atherosclerosis

IRE1α induced senescence promote endothelial barrier dysfunction in diabetes-induced atherosclerosis

Platelet hyperactivation and neutrophil extracellular traps promote thrombo-inflammation and glomerular endothelial dysfunction in diabetic kidney disease

Direct oral anticoagulants cause placental vascular abnormalities and epigenetic reprogramming in placenta and the offspring

Islam, M M

Low resolution cryo-EM maps and AFM analysis combined with alpha fold model of full-length coagulation Factor VIII sheds light on the conformational positioning of the Factor VIII B domain

An improved understanding of native coagulation factor XIII complex structure using cryo-EM

Analyzing secretion-based patterns of the heterozygous species of coagulation Factor XIII B cysteine mutations reported from mild FXIII deficiency using confocal microscopy

Ismail, M A

The effect of prophylactic corticosteroid treatment on adeno-associated virus-mediated gene therapy and potential mechanisms of action

Itzler, F R

Improvements in health-related quality of life in adults with severe or moderately severe haemophilia B after receiving etranacogene dezaparvovec gene therapy

Jaffal, H

Measurement of procoagulant platelets in platelet-rich plasma by flow cytometer for the diagnosis of heparin-induced thrombocytopenia

Jahn, K

Role of Neuraminidase A of S. pneumoniae on platelet-bacteria-interaction

Jain, A

Phase 3 study of the efficacy, pharmacokinetics, immunogenicity and safety of von Willebrand Factor/Factor VIII concentrate in patients with severe von Willebrand Disease under 6 years of age

Jamil, MA

Intrinsic difference in cellular response between full-length and B-domain deleted FVIII HEK293 secreting cells: implication for gene therapy

Janata-Schwatczek, K

Characteristics, management, disposition, and outcome of patients with pulmonary embolism in a tertiary care setting

Janbain, M

Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A

Janssen, D

Utility of ACMG classification to support interpretation of molecular genetic test results in patients with FVII deficiency

Jarosch, C

Diagnostic challenges of Thrombotic Thrombocytopenic Purpura: Results from a cohort of 3,100 individual patients in a time period of 21 months

Javed, H

Low resolution cryo-EM maps and AFM analysis combined with alpha fold model of full-length coagulation Factor VIII sheds light on the conformational positioning of the Factor VIII B domain

An improved understanding of native coagulation factor XIII complex structure using cryo-EM

Analyzing secretion-based patterns of the heterozygous species of coagulation Factor XIII B cysteine mutations reported from mild FXIII deficiency using confocal microscopy

Jayaram, K

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Jimenez, V Yuste

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

Jiménez, V Yuste

Patient-reported symptoms to predict intra-articular location of joint bleeds

Jiménez-Yuste, V

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Jurado-Mestre, B

Influenza infections destabilize established immune tolerance in HemA mice

Juranek, S

Switching to extended half-life rFVIIIfc: transition of therapy and pharmacokinetics in pediatric patients with severe hemophilia A

Patient-reported symptoms to predict intra-articular location of joint bleeds

Jurk, K

Discriminatory potential of platelet function reference ranges in cardiovascular disease

A hierarchical network of Src, Syk, Btk and PKC controls GPVI-dependent human platelet activation

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

Platelet responsiveness in the post-acute phase of pulmonary embolism

Kaijen, P

Exploring red blood cells as a novel tolerogenic approach for Factor VIII inhibitors employing immuno-dominant FVIII derived peptides presented on MHC class II

Kappert, G

A single-centre approach for a safe and individualized tolerization phase for the treatment of PUPs with severe haemophilia A

Impaired signaling pathways in Glanzmann thrombasthenia platelets

The phenotypic and genetic assessment of hereditary antithrombin deficiency in 215 patients from the Rhein-Ruhr area in Germany

Karakuyu, A

Measurement of procoagulant platelets in platelet-rich plasma by flow cytometer for the diagnosis of heparin-induced thrombocytopenia

Karastaneva, A

Platelet expression of the transcription factor ETV6 points toward ETV6-related thrombocytopenia and can be detected by immunofluorescence on the blood smear

Kausche, E L

Bridging the gap between coagulation in experimental research and clinical hemostaseology – a modified rotational thromboelastometry assay to show the pro-coagulatory effect of senescence on human blood

Kehr, S

Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

Keller, K

Air pollution impacts on in-hospital case-fatality rate of ischemic stroke patients

Mansoor’s self-report tool for cardiovascular risk assessment predicts adverse in-hospital events in patients with pulmonary embolism

Keller-Stanislawski, B

Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

Kempf, W

Participation of T helper cell-mediated negative regulation of coagulation in human arterial thrombosis

Kenet, G

Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

Kentouch, K

PreviouslyuntreatedpatientsinGermany2017 - 2021 – Update 2022

Kern, R

Use of DOAC Dipstick point-of-care testing in patients with acute stroke and transient ischemic attack

Kessler, C

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Key, N

Durability of Factor IX activity and bleeding rate in people with severe or moderately severe haemophilia B after long-term follow-up in the phase 1/2 Study of AMT-060, and phase 2b and phase 3 studies of etranacogene dezaparvovec (AMT-061)

Key, S N

Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B

Khan, E

Tumour derived prothrombin interacts with tumour PAR1 receptors

Alternative polyadenylation regulates VEGF-coreceptor NRP1

Khan, O

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Khoo, T-L

Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1

Khuu, MP

Gut microbiota promotes arterial thrombus formation in hyperlipidemic Ldlr-/- mouse model

Kiessig, T S

A novel solid phase assay for the detection of fibrinolytic activities

Kiialainen, A

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

Kim, Nari

Comparative transcriptome profile analysis on early T2DM-aggravated atherosclerotic mouse aortas

Kiouptsi, K

Gut microbiota promotes arterial thrombus formation in hyperlipidemic Ldlr-/- mouse model

Kirschall, J

Establishment of an ex vivo assay to investigate thrombus formation using platelet concentrates

Kittel, M

Thrombocytopenia in patients with cardiogenic shock treated with extracorporal life support system versus conservative treatment

Klamroth, R

Efficacy of emicizumab prophylaxis in patients with severe hemophilia A in Germany: Follow-up evaluation of real-life-data documented by smart medication eDiary

A snapshot analysis of a prospective, non-interventional study to evaluate real-life prophylactic treatment schedules of factor VIII concentrates

Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec (CSL222) vs. extended half-life Factor IX therapies for severe or moderately severe hemophilia B

Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1

Klauser-Braun, R

Telomere length is associated with increased risk of cardiovascular events in hemodialysis patients

Prevention of coronary and peripheral arterial events in patients with end-stage kidney disease on hemodialysis: prospective results of the VIVALDI study

Klee, J

Comparison of closure time and whole blood impedance aggregometry to light transmission platelet aggregometry for the assessment of platelet response to aspirin and P2Y12 inhibitor therapies: a large-scale study in the outpatient population

Klein, C

Preanalytical quenching of FVIII using FVIII-inhibitors improves the specificity of functional emicizumab testing

Klok, A F

The Post-VTE Functional Status Scale for assessment of functional limitations in patients with venous thromboembolism: construct validity and responsiveness in a prospective cohort study

Knabbe, C

Impaired signaling pathways in Glanzmann thrombasthenia platelets

Plasma-derived extracellular vesicles: a look at the preanalytics

Aspirin resistance and higher risk of pump thrombosis in patients with ventricular assist device – a 7-year follow up study

Knöbl, P

Saliva and urine from persons with hemophilia A trigger coagulation bypassing factor VIII

Neonatal exchange transfusion: hereditary thrombotic thrombocytopenic purpura (hTTP) should be in the differential diagnosis

Knöfler, R

Immune tolerance achievement by low dose factor VIII in PUPs and MTPs under prophylaxis with emicizumab: two case reports

Knowles, M L

Blood-induced inflammation in hemophilia

Koch, T

Monitoring of argatroban in COVID-19 ICU patients: a prospective study comparing aPTT, point-of-care viscoelastic testing with ECA-test and dTT to LC/MS/MS

Monitoring of unfractionated heparin in critical ill ICU patients: a prospective study comparing aPTT and point-of-care viscoelastic testing with IN /HI ratio to anti-Xa

Koder, S

Tissue Factor Pathway Inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer

Koenigs, C

Survey on the care reality of people with mild hemophilia A and B in Germany - the burden of mild hemophilia

Kohler, P T

Role of Neuraminidase A of S. pneumoniae on platelet-bacteria-interaction

Köhler, C

Periinterventional management of edoxaban in major procedures: results from the DRESDEN NOAC REGISTRY

Treatment of VTE with rivaroxaban in adolescents – long-term results from the prospective Dresden NOAC Registry (NCT01588119)

Kohli, S

Platelet hyperactivation and neutrophil extracellular traps promote thrombo-inflammation and glomerular endothelial dysfunction in diabetic kidney disease

Direct oral anticoagulants cause placental vascular abnormalities and epigenetic reprogramming in placenta and the offspring

Königs, C

Production of FVIII-specific iTregs using tolerogenic dendritic cells

Characterization of the influence of heat- and acid-treatment on the FVIII-antibody interaction in order to improve inhibitor diagnostics

Establishment of a flow-cytometry panel to analyse binding of FVIII to lymphocyte populations

Second- and third-generation FVIII-specific CAR Treg responses to FVIII are functionally affected by the combination of FVIII-specific scFvs and intracellular costimulatory domains

Isolation of vWF-specific antibody fragments from phage-displayed scFv libraries

PreviouslyuntreatedpatientsinGermany2017 - 2021 – Update 2022

Königsbrügge, O

Relation of FVIII activity levels with global assays of hemostasis in persons with hemophilia A

The Post-VTE Functional Status Scale for assessment of functional limitations in patients with venous thromboembolism: construct validity and responsiveness in a prospective cohort study

Telomere length is associated with increased risk of cardiovascular events in hemodialysis patients

Prevention of coronary and peripheral arterial events in patients with end-stage kidney disease on hemodialysis: prospective results of the VIVALDI study

Konstantinides, V S

Platelet responsiveness in the post-acute phase of pulmonary embolism

Koparkar, S

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Körber, S

Genetic background of von Willebrand disease

Kornemann, E-M

Biallelic GNE variants in patients with congenital thrombocytopenia

Kotov, V

Influenza infections destabilize established immune tolerance in HemA mice

Kowalski, J

Diagnostic challenges of Thrombotic Thrombocytopenic Purpura: Results from a cohort of 3,100 individual patients in a time period of 21 months

Kraemmer, D

Relation of FVIII activity levels with global assays of hemostasis in persons with hemophilia A

Saliva and urine from persons with hemophilia A trigger coagulation bypassing factor VIII

Krafft, A

Recombinant ADAMTS13 treatment in a pregnant patient with hereditary thrombotic thrombocytopenic purpura

Kraler, S

Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer

Kreidenweiss, A

Platelets are pre-activated during thrombocytopenia in a subset of early malaria infections

Kremer Hovinga, A J

Biobanking for testing hemostasis: Long-term stability of citrated plasma samples

Kremer Hovinga, JA

Recombinant ADAMTS13 treatment in a pregnant patient with hereditary thrombotic thrombocytopenic purpura

Neonatal exchange transfusion: hereditary thrombotic thrombocytopenic purpura (hTTP) should be in the differential diagnosis

Limited concordance of heparin/PF4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study

Kremsner, G P

Platelets are pre-activated during thrombocytopenia in a subset of early malaria infections

Krug, H

Polymer anchors with responsive heparin release for the anticoagulant decoration of hemodialysis membranes

Krüger, L

Role of Neuraminidase A of S. pneumoniae on platelet-bacteria-interaction

Krüggeler, M J

Correlation between von Willebrand Factor and the PI3K/Akt signalling pathway in the control of angiogenesis

Kuanyshbek, A

Investigating the interaction of circulating von Willebrand factor with polymorphonuclear leukocytes ex vivo

Kuijpers, M

A hierarchical network of Src, Syk, Btk and PKC controls GPVI-dependent human platelet activation

Kurts, C

Influenza infections destabilize established immune tolerance in HemA mice

Lackner, J K

Discriminatory potential of platelet function reference ranges in cardiovascular disease

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

Platelet responsiveness in the post-acute phase of pulmonary embolism

Lackner, K J

Conclusion from 50 years of reports on prekallikrein or high-molecular-weight kininogen deficiency

Lackner, M

Pharmacological targeting of ACKR3/CXCR7 enhances anticoagulant acylcarnitine levels in platelets and modulates thrombotic response to lipids

Lacroix-Desmazes, S

Induction of neonatal tolerance to therapeutic FVIII in hemophilia A

Exploring red blood cells as a novel tolerogenic approach for Factor VIII inhibitors employing immuno-dominant FVIII derived peptides presented on MHC class II

Laffan, M

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Lämmerhofer, M

Pharmacological targeting of ACKR3/CXCR7 enhances anticoagulant acylcarnitine levels in platelets and modulates thrombotic response to lipids

Lämmle, B

Conclusion from 50 years of reports on prekallikrein or high-molecular-weight kininogen deficiency

Neonatal exchange transfusion: hereditary thrombotic thrombocytopenic purpura (hTTP) should be in the differential diagnosis

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

Lang, I

Characteristics, management, disposition, and outcome of patients with pulmonary embolism in a tertiary care setting

Lang, P

HSCT in a newborn suffering from SCID and severe haemophilia A

Langer, F

BMS-262084, a FXIa inhibitor, interferes with tumor cell-induced coagulation activation only in tumor cells with low tissue factor (TF) procoagulant activity (PCA)

Expression and release of tumor cell tissue factor triggers recurrent thromboembolism in a patient with endometrial cancer

Langheinrich, T

Participation of T helper cell-mediated negative regulation of coagulation in human arterial thrombosis

Lapikova-Bryhinska, T

Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer

Laschke, W M

Blood-induced inflammation in hemophilia

Lattimore, S

Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B

Lau, K

Interim 52-Week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A

Non-clinical pharmacodynamic effects and immunogenicity assessment of prophylactic immune modulation prior to gene therapy dose administration in C57BL/6 mice

Leavitt, A

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Lee, S

Bridging the gap between coagulation in experimental research and clinical hemostaseology – a modified rotational thromboelastometry assay to show the pro-coagulatory effect of senescence on human blood

Leebeek, WG F

Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B

Lehle, M

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

Lehr, C

BMS-262084, a FXIa inhibitor, interferes with tumor cell-induced coagulation activation only in tumor cells with low tissue factor (TF) procoagulant activity (PCA)

Leineweber, K

Platelet responsiveness in the post-acute phase of pulmonary embolism

Leinøe, E

Platelet expression of the transcription factor ETV6 points toward ETV6-related thrombocytopenia and can be detected by immunofluorescence on the blood smear

Leipold, A

Biallelic GNE variants in patients with congenital thrombocytopenia

Leisinger, E

Recombinant ADAMTS13 treatment in a pregnant patient with hereditary thrombotic thrombocytopenic purpura

Lelieveld, J

Air pollution impacts on in-hospital case-fatality rate of ischemic stroke patients

Lemons, R

Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B

Lennartz, M

Expression and release of tumor cell tissue factor triggers recurrent thromboembolism in a patient with endometrial cancer

Lepatan, M L

Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B

Li, Y

Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B

Liberale, L

Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer

Licht, A

Recombinant ADAMTS13 treatment in a pregnant patient with hereditary thrombotic thrombocytopenic purpura

Lieftüchter, V

Switching to extended half-life rFVIIIfc: transition of therapy and pharmacokinetics in pediatric patients with severe hemophilia A

Linhoff, T

Real-world experience on the use of rIX-FP in patients with hemophilia B: interim results from a prospective, non-interventional study in Germany

Llevadot, R

Developing an assay to distinguish between HIT and VITT antibodies

Lohse, J

Immune tolerance achievement by low dose factor VIII in PUPs and MTPs under prophylaxis with emicizumab: two case reports

Londhe, V

Understanding the biomolecular corona formation at the nano-bio interface

Long, B

Interim 52-Week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A

Non-clinical pharmacodynamic effects and immunogenicity assessment of prophylactic immune modulation prior to gene therapy dose administration in C57BL/6 mice

Loos, K

In-vitro and In-silico characterization of a pathogenic variant in integrin β3 associated with hereditary macrothrombocytopenia

Lorenz, M

Telomere length is associated with increased risk of cardiovascular events in hemodialysis patients

Prevention of coronary and peripheral arterial events in patients with end-stage kidney disease on hemodialysis: prospective results of the VIVALDI study

Loßnitzer, D

Evaluation of the protein C pathway in critically ill patients with severe COVID-19 as compared to bacterial sepsis

Luo, J

Participation of T helper cell-mediated negative regulation of coagulation in human arterial thrombosis

Lüscher, T

Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer

Luxembourg, B

Factor V Leiden paradox in Factor V Leiden homozygotes – a retrospective cohort study

Luz, B

Anti-PF4 antibodies after SARS-CoV-2 vaccines: long term follow-up

Ma, B

Low resolution cryo-EM maps and AFM analysis combined with alpha fold model of full-length coagulation Factor VIII sheds light on the conformational positioning of the Factor VIII B domain

Madan, B

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Mäder, J

BMS-262084, a FXIa inhibitor, interferes with tumor cell-induced coagulation activation only in tumor cells with low tissue factor (TF) procoagulant activity (PCA)

Maegdefessel, L

Participation of T helper cell-mediated negative regulation of coagulation in human arterial thrombosis

Maettler, T C

Inhibition of cold-induced apoptosis of platelet concentrates improves platelet functionality and half-life

Mahlangu, J

Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Mailer, R

Liver damage promotes thromboinflammatory T-cell responses

Mairhofer, M

Bridging the gap between coagulation in experimental research and clinical hemostaseology – a modified rotational thromboelastometry assay to show the pro-coagulatory effect of senescence on human blood

Maitz, MF

Polymer anchors with responsive heparin release for the anticoagulant decoration of hemodialysis membranes

Malakeh, J

Possible immune reaction to COVID-19 vaccination - a case report

Male, C

Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B

Mancuso, M E

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

Marandiuc, D

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

Marchetti, M

Sequential combinations of rapid immunoassays for quick recognition of heparin-induced thrombocytopenia

Utility of D-dimers in the diagnostic work-up of heparin-induced thrombocytopenia (HIT)

Marchi Cappelletti, R

Emicizumab phamacodynamics assessed by thrombin generation and fibrin clot formation

Marini, I

Severe bleeding in a young patient with mild thrombocytopenia due to a novel mutation in growth factor inhibitor 1B

Platelets are pre-activated during thrombocytopenia in a subset of early malaria infections

Establishment of an ex vivo assay to investigate thrombus formation using platelet concentrates

Inhibition of cold-induced apoptosis of platelet concentrates improves platelet functionality and half-life

Measurement of procoagulant platelets in platelet-rich plasma by flow cytometer for the diagnosis of heparin-induced thrombocytopenia

Marquardt, N

Preanalytical quenching of FVIII using FVIII-inhibitors improves the specificity of functional emicizumab testing

Digital joint discovery tool to support hemophilia patient education

Marten, S

Periinterventional management of edoxaban in major procedures: results from the DRESDEN NOAC REGISTRY

Treatment of VTE with rivaroxaban in adolescents – long-term results from the prospective Dresden NOAC Registry (NCT01588119)

Mason, J

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Matsumoto, M

Neonatal exchange transfusion: hereditary thrombotic thrombocytopenic purpura (hTTP) should be in the differential diagnosis

Matsushita, T

Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A

Matthey-Guirao, E

Sequential combinations of rapid immunoassays for quick recognition of heparin-induced thrombocytopenia

Utility of D-dimers in the diagnostic work-up of heparin-induced thrombocytopenia (HIT)

Matulac, Mark John

Comparative transcriptome profile analysis on early T2DM-aggravated atherosclerotic mouse aortas

Matzdorff, A

A Survey on anticoagulation in patient with ITP

Matzner, J F

Biallelic GNE variants in patients with congenital thrombocytopenia

Mayr, T

Characteristics, management, disposition, and outcome of patients with pulmonary embolism in a tertiary care setting

McKeand, W

Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B

McRae, HL

Elevated plasminogen activator inhibitor-1 is not associated with impaired plasmin formation and thrombotic risk after low-grade coagulation activation in vivo

McRae, L H

Evaluation of the protein C pathway in critically ill patients with severe COVID-19 as compared to bacterial sepsis

Comparison of closure time and whole blood impedance aggregometry to light transmission platelet aggregometry for the assessment of platelet response to aspirin and P2Y12 inhibitor therapies: a large-scale study in the outpatient population

Mdawar-Bailly, É

Evaluating the individual risk of venous thrombo-embolism in patients with liver cirrhosis: Usefulness of in vivo and ex vivo thrombin generation parameters

Mehic, D

Vitamin D deficiency in adult patients with primary immune thrombocytopenia (ITP) from the Vienna ITP Biobank

Impaired hemostatic capacity in patients with low von Willebrand factor

Mehlig-Warnecke, N

Monitoring of argatroban in COVID-19 ICU patients: a prospective study comparing aPTT, point-of-care viscoelastic testing with ECA-test and dTT to LC/MS/MS

Meijer, K

Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A

Meinhardt, A

Assessment of platelet abnormalities in patients with DiGeorge Syndrome by immunofluorescence microscopy on the blood smear

Mendez, A

Limited concordance of heparin/PF4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study

Menger, D M

Blood-induced inflammation in hemophilia

Messmer, X

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

Meyer, B

Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

Meyer, O

A Survey on anticoagulation in patient with ITP

Miebach, G

Switching to extended half-life rFVIIIfc: transition of therapy and pharmacokinetics in pediatric patients with severe hemophilia A

Miesbach, W

Survey on the care reality of people with mild hemophilia A and B in Germany - the burden of mild hemophilia

Development of an in-house ELISA method for determining the anti-capsid AAV IgG titerin blood donors and hemophilic patients

Investigation Of endometriosis symptoms and tumor marker CA 125 in patients With hereditary Von Willebrand disease

Genetic background of von Willebrand disease

Durability of Factor IX activity and bleeding rate in people with severe or moderately severe haemophilia B after long-term follow-up in the phase 1/2 Study of AMT-060, and phase 2b and phase 3 studies of etranacogene dezaparvovec (AMT-061)

Randomized-controlled cross-over pilot study on the effectiveness of manual lymphatic drainage in patients with hemophilic arthropathy

Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B

HEM-POWR study: Subgroup analysis evaluating the real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Germany

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Factor V Leiden paradox in Factor V Leiden homozygotes – a retrospective cohort study

The predictive value of coagulation parameters for the course of disease in COVID-19 patients

Milanov, P

Development of an in-house ELISA method for determining the anti-capsid AAV IgG titerin blood donors and hemophilic patients

Miller, C J

Improvements in health-related quality of life in adults with severe or moderately severe haemophilia B after receiving etranacogene dezaparvovec gene therapy

Mimoun, A

Induction of neonatal tolerance to therapeutic FVIII in hemophilia A

Minařík, J

Markers of coagulopathy in multiple myeloma

Mink, S

Use of DOAC Dipstick point-of-care testing in patients with acute stroke and transient ischemic attack

Miranda, M

Exploring red blood cells as a novel tolerogenic approach for Factor VIII inhibitors employing immuno-dominant FVIII derived peptides presented on MHC class II

Mitchell, I

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Möhnle, P

The beauty of real-world data. EHL factor concentrates contribute to declining annual bleed rates

Moik, F

Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer

Tissue Factor Pathway Inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer

Mojzisch, A

Analysis of single nucleotide polymorphisms in the C4 domain of vWF reveals the novel gain-of-function variant p.Ser2564Arg

Monahan, E P

Improvements in health-related quality of life in adults with severe or moderately severe haemophilia B after receiving etranacogene dezaparvovec gene therapy

Durability of Factor IX activity and bleeding rate in people with severe or moderately severe haemophilia B after long-term follow-up in the phase 1/2 Study of AMT-060, and phase 2b and phase 3 studies of etranacogene dezaparvovec (AMT-061)

Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B

Monahan, P

Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec (CSL222) vs. extended half-life Factor IX therapies for severe or moderately severe hemophilia B

Monahan, PE

Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Mondorf, C

Treatment of a patient with von Willebrand disease type 2B and severe thrombocytopenia due to mutation p.V1316M with thrombopoietin receptor agonist Avatrombopag

Mondorf, W

Changes in hemophilia A therapy - an analysis of real-world data from smart medication eDiary over the past 10 years

Efficacy of emicizumab prophylaxis in patients with severe hemophilia A in Germany: Follow-up evaluation of real-life-data documented by smart medication eDiary

Treatment of a patient with von Willebrand disease type 2B and severe thrombocytopenia due to mutation p.V1316M with thrombopoietin receptor agonist Avatrombopag

Montecucco, F

Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer

Moorehead, P

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Moradpour, D

Evaluating the individual risk of venous thrombo-embolism in patients with liver cirrhosis: Usefulness of in vivo and ex vivo thrombin generation parameters

In vitro efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis

Mott, K

Distinct functional defects in platelet subpopulations after hematopoietic stem cell transplantation

Ontogeny of peripheral blood platelet GPIIb/IIIa activation and granule release in preterm and term neonates

Mouhish, Y

Tumour derived prothrombin interacts with tumour PAR1 receptors

Mubeen, S

Heme-triggered effects on blood coagulation: a bioinformatics approach based on experimental data

Müller, J

Preanalytical quenching of FVIII using FVIII-inhibitors improves the specificity of functional emicizumab testing

Elevated plasminogen activator inhibitor-1 is not associated with impaired plasmin formation and thrombotic risk after low-grade coagulation activation in vivo

Evaluation of the protein C pathway in critically ill patients with severe COVID-19 as compared to bacterial sepsis

Comparison of closure time and whole blood impedance aggregometry to light transmission platelet aggregometry for the assessment of platelet response to aspirin and P2Y12 inhibitor therapies: a large-scale study in the outpatient population

Müller, M

Gut microbiota promotes arterial thrombus formation in hyperlipidemic Ldlr-/- mouse model

Müller, S

Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

Müller-Calleja, N

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

Münzel, T

Air pollution impacts on in-hospital case-fatality rate of ischemic stroke patients

Discriminatory potential of platelet function reference ranges in cardiovascular disease

Mansoor’s self-report tool for cardiovascular risk assessment predicts adverse in-hospital events in patients with pulmonary embolism

Platelet responsiveness in the post-acute phase of pulmonary embolism

Murphy, R

The effect of prophylactic corticosteroid treatment on adeno-associated virus-mediated gene therapy and potential mechanisms of action

Nagler, M

Biobanking for testing hemostasis: Long-term stability of citrated plasma samples

Limited concordance of heparin/PF4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study

Naue, C

Periinterventional management of edoxaban in major procedures: results from the DRESDEN NOAC REGISTRY

Treatment of VTE with rivaroxaban in adolescents – long-term results from the prospective Dresden NOAC Registry (NCT01588119)

Negrier, C

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Nguyen, S T

Endothelial protein C receptor signaling regulates myeloid-biased hematopoiesis under stress and in aging

Nieuwland, R

Saliva and urine from persons with hemophilia A trigger coagulation bypassing factor VIII

Nilius, H

Biobanking for testing hemostasis: Long-term stability of citrated plasma samples

Limited concordance of heparin/PF4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study

Nopp, S

The Post-VTE Functional Status Scale for assessment of functional limitations in patients with venous thromboembolism: construct validity and responsiveness in a prospective cohort study

Characteristics, management, disposition, and outcome of patients with pulmonary embolism in a tertiary care setting

Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer

Nourse, J

Tumour derived prothrombin interacts with tumour PAR1 receptors

Alternative polyadenylation regulates VEGF-coreceptor NRP1

Nowak-Göttl, U

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Nowak-Harnau, S

Inhibition of cold-induced apoptosis of platelet concentrates improves platelet functionality and half-life

Nürnberg, B

Pharmacological targeting of ACKR3/CXCR7 enhances anticoagulant acylcarnitine levels in platelets and modulates thrombotic response to lipids

Nusgen, N

The effects of single and combined knockouts of GABARAPs proteins family on FVIII secretion

Nüsgen, N

Intrinsic difference in cellular response between full-length and B-domain deleted FVIII HEK293 secreting cells: implication for gene therapy

Obrochta, K

Non-clinical pharmacodynamic effects and immunogenicity assessment of prophylactic immune modulation prior to gene therapy dose administration in C57BL/6 mice

Oertel, R

Monitoring of argatroban in COVID-19 ICU patients: a prospective study comparing aPTT, point-of-care viscoelastic testing with ECA-test and dTT to LC/MS/MS

Ohlenforst, S

Aggregates of non-muscle myosin IIA in the erythrocytes associate with GATA1-related thrombocytopenia

Oldenburg, J

The effects of single and combined knockouts of GABARAPs proteins family on FVIII secretion

Real-world experience on the use of rIX-FP in patients with hemophilia B: interim results from a prospective, non-interventional study in Germany

Patient-reported symptoms to predict intra-articular location of joint bleeds

Preanalytical quenching of FVIII using FVIII-inhibitors improves the specificity of functional emicizumab testing

A snapshot analysis of a prospective, non-interventional study to evaluate real-life prophylactic treatment schedules of factor VIII concentrates

Intrinsic difference in cellular response between full-length and B-domain deleted FVIII HEK293 secreting cells: implication for gene therapy

Establishment and specification analysis of LSEC-like endothelial cells for the detection of endogenous FVIII

Correlation between coagulation factor residual activities and detection rate of diseasecausing variants in Rare Bleeding Disorders

Investigating the interaction of circulating von Willebrand factor with polymorphonuclear leukocytes ex vivo

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Influenza infections destabilize established immune tolerance in HemA mice

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

In-vitro and In-silico characterization of a pathogenic variant in integrin β3 associated with hereditary macrothrombocytopenia

Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B

Digital joint discovery tool to support hemophilia patient education

HEM-POWR study: Subgroup analysis evaluating the real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Germany

Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

EMIIL - Non-interventional study to investigate the effectiveness of Emicizumab under real-world conditions in pediatric, adolescent, adult and elderly patients with hemophilia A (PwHA) with and without FVIII inhibitors: an interim analysis

Low resolution cryo-EM maps and AFM analysis combined with alpha fold model of full-length coagulation Factor VIII sheds light on the conformational positioning of the Factor VIII B domain

Pain in patients with hereditary bleeding disorders: evaluation of a survey among people affected in Germany

An improved understanding of native coagulation factor XIII complex structure using cryo-EM

Analyzing secretion-based patterns of the heterozygous species of coagulation Factor XIII B cysteine mutations reported from mild FXIII deficiency using confocal microscopy

Elevated plasminogen activator inhibitor-1 is not associated with impaired plasmin formation and thrombotic risk after low-grade coagulation activation in vivo

Evaluation of the protein C pathway in critically ill patients with severe COVID-19 as compared to bacterial sepsis

Comparison of closure time and whole blood impedance aggregometry to light transmission platelet aggregometry for the assessment of platelet response to aspirin and P2Y12 inhibitor therapies: a large-scale study in the outpatient population

Olivieri, M

Switching to extended half-life rFVIIIfc: transition of therapy and pharmacokinetics in pediatric patients with severe hemophilia A

Survey on the care reality of people with mild hemophilia A and B in Germany - the burden of mild hemophilia

Real-world experience on the use of rIX-FP in patients with hemophilia B: interim results from a prospective, non-interventional study in Germany

PreviouslyuntreatedpatientsinGermany2017 - 2021 – Update 2022

Orlowski, A

Production of FVIII-specific iTregs using tolerogenic dendritic cells

Establishment of a flow-cytometry panel to analyse binding of FVIII to lymphocyte populations

Second- and third-generation FVIII-specific CAR Treg responses to FVIII are functionally affected by the combination of FVIII-specific scFvs and intracellular costimulatory domains

Isolation of vWF-specific antibody fragments from phage-displayed scFv libraries

Ostad, A M

Mansoor’s self-report tool for cardiovascular risk assessment predicts adverse in-hospital events in patients with pulmonary embolism

Ozelo, M

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Pabinger, I

Relation of FVIII activity levels with global assays of hemostasis in persons with hemophilia A

Vitamin D deficiency in adult patients with primary immune thrombocytopenia (ITP) from the Vienna ITP Biobank

Impaired hemostatic capacity in patients with low von Willebrand factor

Saliva and urine from persons with hemophilia A trigger coagulation bypassing factor VIII

The Post-VTE Functional Status Scale for assessment of functional limitations in patients with venous thromboembolism: construct validity and responsiveness in a prospective cohort study

Telomere length is associated with increased risk of cardiovascular events in hemodialysis patients

Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer

Tissue Factor Pathway Inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer

Prevention of coronary and peripheral arterial events in patients with end-stage kidney disease on hemodialysis: prospective results of the VIVALDI study

Pagel, S

Immune modulation by the endothelial protein C receptor (EPCR) in cancer progression

Paliwal, Y

Global seroprevalence of neutralizing antibodies against adeno-associated virus (AAV) serotypes of relevance to gene therapy

Palla, R

The effect of DNA methylation on inhibitor development in haemophilia A patients treated with FVIII concentrates

Pammer, M

Bridging the gap between coagulation in experimental research and clinical hemostaseology – a modified rotational thromboelastometry assay to show the pro-coagulatory effect of senescence on human blood

Panagiota, V

Genetic background of von Willebrand disease

Panova-Noeva, M

Discriminatory potential of platelet function reference ranges in cardiovascular disease

Platelet responsiveness in the post-acute phase of pulmonary embolism

Papajík, T

Markers of coagulopathy in multiple myeloma

Park, S Y

Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1

Patton, K

Interim 52-Week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A

Pavlova, A

Correlation between coagulation factor residual activities and detection rate of diseasecausing variants in Rare Bleeding Disorders

In-vitro and In-silico characterization of a pathogenic variant in integrin β3 associated with hereditary macrothrombocytopenia

Pekrul, I

The beauty of real-world data. EHL factor concentrates contribute to declining annual bleed rates

Pellequer, J-L

Low resolution cryo-EM maps and AFM analysis combined with alpha fold model of full-length coagulation Factor VIII sheds light on the conformational positioning of the Factor VIII B domain

Pelzl, L

Platelets are pre-activated during thrombocytopenia in a subset of early malaria infections

Establishment of an ex vivo assay to investigate thrombus formation using platelet concentrates

Inhibition of cold-induced apoptosis of platelet concentrates improves platelet functionality and half-life

Measurement of procoagulant platelets in platelet-rich plasma by flow cytometer for the diagnosis of heparin-induced thrombocytopenia

Pepperell, D

Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1

Pereira, C Portela

In vitro efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis

Pereira, PortelaC

Evaluating the individual risk of venous thrombo-embolism in patients with liver cirrhosis: Usefulness of in vivo and ex vivo thrombin generation parameters

Pereira Portela, C

Identification of key regulators of procoagulant COAT platelet generation by quantitative phosphoproteomic analysis and phosphoflow

Petropoulos, J C

Global seroprevalence of neutralizing antibodies against adeno-associated virus (AAV) serotypes of relevance to gene therapy

Peyvandi, F

The effect of DNA methylation on inhibitor development in haemophilia A patients treated with FVIII concentrates

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

Pezeshkpoor, B

Correlation between coagulation factor residual activities and detection rate of diseasecausing variants in Rare Bleeding Disorders

In-vitro and In-silico characterization of a pathogenic variant in integrin β3 associated with hereditary macrothrombocytopenia

Pfrepper, C

Real-world experience on the use of rIX-FP in patients with hemophilia B: interim results from a prospective, non-interventional study in Germany

EMIIL - Non-interventional study to investigate the effectiveness of Emicizumab under real-world conditions in pediatric, adolescent, adult and elderly patients with hemophilia A (PwHA) with and without FVIII inhibitors: an interim analysis

Piccand, M

Interim analysis in patients from Germany and Switzerland of the A-MORE study: a 48-month, multi-centre, observational study to evaluate longterm effectiveness of rFVIIIFc on joint health

Pilch, J

Blood-induced inflammation in hemophilia

Pipe, S

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Pipe, W S

Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1

Improvements in health-related quality of life in adults with severe or moderately severe haemophilia B after receiving etranacogene dezaparvovec gene therapy

Durability of Factor IX activity and bleeding rate in people with severe or moderately severe haemophilia B after long-term follow-up in the phase 1/2 Study of AMT-060, and phase 2b and phase 3 studies of etranacogene dezaparvovec (AMT-061)

Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

Poch, A

Expression and release of tumor cell tissue factor triggers recurrent thromboembolism in a patient with endometrial cancer

Pontarollo, G

Gut microbiota promotes arterial thrombus formation in hyperlipidemic Ldlr-/- mouse model

Portela, CP

The role of Mitochondrial Calcium Uniporter in platelet signalling

Pott, J

Immune modulation by the endothelial protein C receptor (EPCR) in cancer progression

Pötzsch, B

Preanalytical quenching of FVIII using FVIII-inhibitors improves the specificity of functional emicizumab testing

Elevated plasminogen activator inhibitor-1 is not associated with impaired plasmin formation and thrombotic risk after low-grade coagulation activation in vivo

Evaluation of the protein C pathway in critically ill patients with severe COVID-19 as compared to bacterial sepsis

Comparison of closure time and whole blood impedance aggregometry to light transmission platelet aggregometry for the assessment of platelet response to aspirin and P2Y12 inhibitor therapies: a large-scale study in the outpatient population

Preinstorfer, S

Developing an assay to determine the individual osteoclastogenic potential of patients with coagulation disorders in-vitro: challenges and pitfalls

Preisler, B

Correlation between coagulation factor residual activities and detection rate of diseasecausing variants in Rare Bleeding Disorders

Preusser, M

Tissue Factor Pathway Inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer

Prochaska, H J

Platelet responsiveness in the post-acute phase of pulmonary embolism

Prochaska, J H

Discriminatory potential of platelet function reference ranges in cardiovascular disease

Procházková, J

Can APC inhibition by lupus anticoagulants indicate antibody thrombogenicity?

Prodinger, G

A sensitive and selective method for the measurement of activated factor X based on complex formation with tissue factor pathway inhibitor

Putensen, C

Evaluation of the protein C pathway in critically ill patients with severe COVID-19 as compared to bacterial sepsis

Quehenberger, P

Relation of FVIII activity levels with global assays of hemostasis in persons with hemophilia A

Vitamin D deficiency in adult patients with primary immune thrombocytopenia (ITP) from the Vienna ITP Biobank

Impaired hemostatic capacity in patients with low von Willebrand factor

Quinn, P

A novel solid phase assay for the detection of fibrinolytic activities

Quon, D

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Quon, D V

Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1

Rackè, B

Utility of ACMG classification to support interpretation of molecular genetic test results in patients with FVII deficiency

Radev, M

Participation of T helper cell-mediated negative regulation of coagulation in human arterial thrombosis

Ramaraje, SU urs

Low resolution cryo-EM maps and AFM analysis combined with alpha fold model of full-length coagulation Factor VIII sheds light on the conformational positioning of the Factor VIII B domain

Ramaraje, Urs S U

Analyzing secretion-based patterns of the heterozygous species of coagulation Factor XIII B cysteine mutations reported from mild FXIII deficiency using confocal microscopy

Ramaraje Urs, S U

An improved understanding of native coagulation factor XIII complex structure using cryo-EM

Rana, R

Hypercoagulability impairs plaque stability in diabetes-induced atherosclerosis

Ransmann, P

Insights in pain processing of affected versus non-affected structures

Rapp, S

Discriminatory potential of platelet function reference ranges in cardiovascular disease

Rasko, J

Global seroprevalence of neutralizing antibodies against adeno-associated virus (AAV) serotypes of relevance to gene therapy

Rastguye Haghi, S H

Air pollution impacts on in-hospital case-fatality rate of ischemic stroke patients

Rath, M

Establishment and specification analysis of LSEC-like endothelial cells for the detection of endogenous FVIII

A novel, homozygous mutation in GFI1B causing inherited thrombocytopenia with Glanzmann-like platelet dysfunction

Rauchfuß, S

Development of an in-house ELISA method for determining the anti-capsid AAV IgG titerin blood donors and hemophilic patients

Investigation Of endometriosis symptoms and tumor marker CA 125 in patients With hereditary Von Willebrand disease

Recht, M

Durability of Factor IX activity and bleeding rate in people with severe or moderately severe haemophilia B after long-term follow-up in the phase 1/2 Study of AMT-060, and phase 2b and phase 3 studies of etranacogene dezaparvovec (AMT-061)

Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B

Reda, S

Elevated plasminogen activator inhibitor-1 is not associated with impaired plasmin formation and thrombotic risk after low-grade coagulation activation in vivo

Comparison of closure time and whole blood impedance aggregometry to light transmission platelet aggregometry for the assessment of platelet response to aspirin and P2Y12 inhibitor therapies: a large-scale study in the outpatient population

Reding, M

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Regenhardt, J

BMS-262084, a FXIa inhibitor, interferes with tumor cell-induced coagulation activation only in tumor cells with low tissue factor (TF) procoagulant activity (PCA)

Reinhardt, C

Gut microbiota promotes arterial thrombus formation in hyperlipidemic Ldlr-/- mouse model

Reinhardt, D

A single-centre approach for a safe and individualized tolerization phase for the treatment of PUPs with severe haemophilia A

Rejtő, J

Relation of FVIII activity levels with global assays of hemostasis in persons with hemophilia A

Renner, B

Monitoring of argatroban in COVID-19 ICU patients: a prospective study comparing aPTT, point-of-care viscoelastic testing with ECA-test and dTT to LC/MS/MS

Reschke, M

Single center experience with emicizumab for primary bleeding prophylaxis in children < 2 years of age with severe hemophilia A

Current diagnostic and therapeutic standard of iliac vein compression syndrome (May-Thurner syndrome) in children, adolescents and young adults. A survey among national thrombosis experts

Reyes, A Ruiz

Induction of neonatal tolerance to therapeutic FVIII in hemophilia A

Richter, H

Efficacy of emicizumab prophylaxis in patients with severe hemophilia A in Germany: Follow-up evaluation of real-life-data documented by smart medication eDiary

Structural alteration and impact on pain perception in patients with haemophilia

Rittener-Ruff, L

Sequential combinations of rapid immunoassays for quick recognition of heparin-induced thrombocytopenia

Rivera, J

Aggregates of non-muscle myosin IIA in the erythrocytes associate with GATA1-related thrombocytopenia

Robinson, T

Interim 52-Week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A

Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Roesch, A

Changes in hemophilia A therapy - an analysis of real-world data from smart medication eDiary over the past 10 years

At the forefront of the introduction of gene therapy in hemophilia A and B: Design and implementation of an innovative software platform ("smart medication Gene") for gene therapy

Rolling, C C

BMS-262084, a FXIa inhibitor, interferes with tumor cell-induced coagulation activation only in tumor cells with low tissue factor (TF) procoagulant activity (PCA)

Roose, E

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

Rosenthal, M

Pain in patients with hereditary bleeding disorders: evaluation of a survey among people affected in Germany

Rossmann, H

Conclusion from 50 years of reports on prekallikrein or high-molecular-weight kininogen deficiency

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

Roth, S

Development of an in-house ELISA method for determining the anti-capsid AAV IgG titerin blood donors and hemophilic patients

Investigation Of endometriosis symptoms and tumor marker CA 125 in patients With hereditary Von Willebrand disease

Rott, H

A single-centre approach for a safe and individualized tolerization phase for the treatment of PUPs with severe haemophilia A

The phenotypic and genetic assessment of hereditary antithrombin deficiency in 215 patients from the Rhein-Ruhr area in Germany

Royce, J

Endothelial protein C receptor signaling regulates myeloid-biased hematopoiesis under stress and in aging

Ruf, W

Saliva and urine from persons with hemophilia A trigger coagulation bypassing factor VIII

Endothelial protein C receptor signaling regulates myeloid-biased hematopoiesis under stress and in aging

Immune modulation by the endothelial protein C receptor (EPCR) in cancer progression

Rugeri, L

Efficacy, safety and consumption of plasma-derived von Willebrand factor (VWF)/Factor VIII (FVIII) concentrate with 2.4:1 VWF:FVIII ratio for the treatment of von Willebrand Disease: a systematic review

Rühl, H

Preanalytical quenching of FVIII using FVIII-inhibitors improves the specificity of functional emicizumab testing

Elevated plasminogen activator inhibitor-1 is not associated with impaired plasmin formation and thrombotic risk after low-grade coagulation activation in vivo

Evaluation of the protein C pathway in critically ill patients with severe COVID-19 as compared to bacterial sepsis

Comparison of closure time and whole blood impedance aggregometry to light transmission platelet aggregometry for the assessment of platelet response to aspirin and P2Y12 inhibitor therapies: a large-scale study in the outpatient population

Ruland, A

Polymer anchors with responsive heparin release for the anticoagulant decoration of hemodialysis membranes

Rupp, M V

Healthcare professionals (HCPs) in Austria are positive about gene therapy, but expressed a need for a more topic related education

Ruppert-Seipp, G

Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

Ruthenberg, J

Single center experience with emicizumab for primary bleeding prophylaxis in children < 2 years of age with severe hemophilia A

Sachs, N

Participation of T helper cell-mediated negative regulation of coagulation in human arterial thrombosis

Sachs, U

Efficacy of emicizumab prophylaxis in patients with severe hemophilia A in Germany: Follow-up evaluation of real-life-data documented by smart medication eDiary

Säemann, M

Telomere length is associated with increased risk of cardiovascular events in hemodialysis patients

Prevention of coronary and peripheral arterial events in patients with end-stage kidney disease on hemodialysis: prospective results of the VIVALDI study

Salzmann-Manrique, E

Characterization of the influence of heat- and acid-treatment on the FVIII-antibody interaction in order to improve inhibitor diagnostics

Samadi, N

Saliva and urine from persons with hemophilia A trigger coagulation bypassing factor VIII

Sanabria, M

Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A

Scatigna, S

Second- and third-generation FVIII-specific CAR Treg responses to FVIII are functionally affected by the combination of FVIII-specific scFvs and intracellular costimulatory domains

Schäfer, K

Gut microbiota promotes arterial thrombus formation in hyperlipidemic Ldlr-/- mouse model

Schäffeler, E

Pharmacological targeting of ACKR3/CXCR7 enhances anticoagulant acylcarnitine levels in platelets and modulates thrombotic response to lipids

Schepperle, C

Pain in patients with hereditary bleeding disorders: evaluation of a survey among people affected in Germany

Schirmer, M

Low bone mineral density in hemophiliacs: cell culture experiments to elucidate the role of coagulation factors in bone metabolism

Schirner, K

Efficacy, safety and consumption of plasma-derived von Willebrand factor (VWF)/Factor VIII (FVIII) concentrate with 2.4:1 VWF:FVIII ratio for the treatment of von Willebrand Disease: a systematic review

Schlachetzki, F

Therapeutic interventions and use of point of care DOAC Dipstick test in stroke patients: an interim analysis of a prospective cohort study

Schlagenhauf, A

Developing an assay to determine the individual osteoclastogenic potential of patients with coagulation disorders in-vitro: challenges and pitfalls

Schlager, O

The Post-VTE Functional Status Scale for assessment of functional limitations in patients with venous thromboembolism: construct validity and responsiveness in a prospective cohort study

Schmaldienst, S

Telomere length is associated with increased risk of cardiovascular events in hemodialysis patients

Prevention of coronary and peripheral arterial events in patients with end-stage kidney disease on hemodialysis: prospective results of the VIVALDI study

Schmid, A

Limited concordance of heparin/PF4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study

Schmidt, A

Insights in pain processing of affected versus non-affected structures

Production of FVIII-specific iTregs using tolerogenic dendritic cells

Characterization of the influence of heat- and acid-treatment on the FVIII-antibody interaction in order to improve inhibitor diagnostics

Establishment of a flow-cytometry panel to analyse binding of FVIII to lymphocyte populations

Second- and third-generation FVIII-specific CAR Treg responses to FVIII are functionally affected by the combination of FVIII-specific scFvs and intracellular costimulatory domains

Isolation of vWF-specific antibody fragments from phage-displayed scFv libraries

Structural alteration and impact on pain perception in patients with haemophilia

Schmidt, K

Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A

Schmidtmann, I

Air pollution impacts on in-hospital case-fatality rate of ischemic stroke patients

Schmitt, C

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

Schmitt, CA

Bridging the gap between coagulation in experimental research and clinical hemostaseology – a modified rotational thromboelastometry assay to show the pro-coagulatory effect of senescence on human blood

Schmitt, H V

Mansoor’s self-report tool for cardiovascular risk assessment predicts adverse in-hospital events in patients with pulmonary embolism

Schmoldt, D

Changes in hemophilia A therapy - an analysis of real-world data from smart medication eDiary over the past 10 years

At the forefront of the introduction of gene therapy in hemophilia A and B: Design and implementation of an innovative software platform ("smart medication Gene") for gene therapy

Schneider, W S

Analysis of single nucleotide polymorphisms in the C4 domain of vWF reveals the novel gain-of-function variant p.Ser2564Arg

Schneppenheim, R

Neonatal exchange transfusion: hereditary thrombotic thrombocytopenic purpura (hTTP) should be in the differential diagnosis

Schneppenheim, S

Diagnostic challenges of Thrombotic Thrombocytopenic Purpura: Results from a cohort of 3,100 individual patients in a time period of 21 months

Schnepper, P

Production of FVIII-specific iTregs using tolerogenic dendritic cells

Schober, S

HSCT in a newborn suffering from SCID and severe haemophilia A

Schönborn, L

Developing an assay to distinguish between HIT and VITT antibodies

Subsequent vaccinations in VITT patients other than SARS-CoV2 vaccination

Schramm, R

Aspirin resistance and higher risk of pump thrombosis in patients with ventricular assist device – a 7-year follow up study

Schramm, T

Vitamin D deficiency in adult patients with primary immune thrombocytopenia (ITP) from the Vienna ITP Biobank

Schröder, M

Correlation between von Willebrand Factor and the PI3K/Akt signalling pathway in the control of angiogenesis

Schulenkorf, A

BMS-262084, a FXIa inhibitor, interferes with tumor cell-induced coagulation activation only in tumor cells with low tissue factor (TF) procoagulant activity (PCA)

Schulte, K

Aspirin resistance and higher risk of pump thrombosis in patients with ventricular assist device – a 7-year follow up study

Schultze-Strasser, S

Establishment of a flow-cytometry panel to analyse binding of FVIII to lymphocyte populations

Second- and third-generation FVIII-specific CAR Treg responses to FVIII are functionally affected by the combination of FVIII-specific scFvs and intracellular costimulatory domains

PreviouslyuntreatedpatientsinGermany2017 - 2021 – Update 2022

Schulze, E Schleithoff

Pain in patients with hereditary bleeding disorders: evaluation of a survey among people affected in Germany

Schulze, H

Distinct functional defects in platelet subpopulations after hematopoietic stem cell transplantation

Ontogeny of peripheral blood platelet GPIIb/IIIa activation and granule release in preterm and term neonates

Schuster, K A

Discriminatory potential of platelet function reference ranges in cardiovascular disease

Schved, J-F

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Schwab, M

Pharmacological targeting of ACKR3/CXCR7 enhances anticoagulant acylcarnitine levels in platelets and modulates thrombotic response to lipids

Schwäble, J

Development of an in-house ELISA method for determining the anti-capsid AAV IgG titerin blood donors and hemophilic patients

Schwarz, L S

The impact of enhanced platelet turnover on platelet reactivity in healthy humans

Schwarz, N

Elevated plasminogen activator inhibitor-1 is not associated with impaired plasmin formation and thrombotic risk after low-grade coagulation activation in vivo

Seck, E S

Subsequent vaccinations in VITT patients other than SARS-CoV2 vaccination

Seeger, S

A snapshot analysis of a prospective, non-interventional study to evaluate real-life prophylactic treatment schedules of factor VIII concentrates

Seidel, G M

Platelet expression of the transcription factor ETV6 points toward ETV6-related thrombocytopenia and can be detected by immunofluorescence on the blood smear

Seifert, W

Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B

Seifreid, E

Genetic background of von Willebrand disease

Seifried, E

Development of an in-house ELISA method for determining the anti-capsid AAV IgG titerin blood donors and hemophilic patients

Seitel, T

Non-clinical pharmacodynamic effects and immunogenicity assessment of prophylactic immune modulation prior to gene therapy dose administration in C57BL/6 mice

Selleng, K

A novel, homozygous mutation in GFI1B causing inherited thrombocytopenia with Glanzmann-like platelet dysfunction

Sereda, N

In-vitro and In-silico characterization of a pathogenic variant in integrin β3 associated with hereditary macrothrombocytopenia

Serra, A

Recombinant ADAMTS13 treatment in a pregnant patient with hereditary thrombotic thrombocytopenic purpura

Serra, J

Developing an assay to distinguish between HIT and VITT antibodies

Severin, K

HEM-POWR study: Subgroup analysis evaluating the real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Germany

Shahidi-Hamedani, N

Preanalytical quenching of FVIII using FVIII-inhibitors improves the specificity of functional emicizumab testing

Elevated plasminogen activator inhibitor-1 is not associated with impaired plasmin formation and thrombotic risk after low-grade coagulation activation in vivo

Shahzad, K

Hypercoagulability impairs plaque stability in diabetes-induced atherosclerosis

IRE1α induced senescence promote endothelial barrier dysfunction in diabetes-induced atherosclerosis

Shapiro, D A

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Shapiro, S

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Shehwar, D

Identification of key regulators of procoagulant COAT platelet generation by quantitative phosphoproteomic analysis and phosphoflow

The role of Mitochondrial Calcium Uniporter in platelet signalling

In vitro efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis

Sheng-Chieh, C

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Sickmann, A

A hierarchical network of Src, Syk, Btk and PKC controls GPVI-dependent human platelet activation

Siebert, M

A single-centre approach for a safe and individualized tolerization phase for the treatment of PUPs with severe haemophilia A

Assessment of health status, quality of life and physiCAL functIoninG of refUgee hemophiLia patients from UkrAine (CALIGULA Study)

Sigl-Kraetzig, M

Structural alteration and impact on pain perception in patients with haemophilia

Sigl-Krätzig, M

Patient-reported symptoms to predict intra-articular location of joint bleeds

Sihn, C-R

The effect of prophylactic corticosteroid treatment on adeno-associated virus-mediated gene therapy and potential mechanisms of action

Singer, H

Establishment and specification analysis of LSEC-like endothelial cells for the detection of endogenous FVIII

Singh, A

Platelets are pre-activated during thrombocytopenia in a subset of early malaria infections

Singh, K K

Platelet hyperactivation and neutrophil extracellular traps promote thrombo-inflammation and glomerular endothelial dysfunction in diabetic kidney disease

Direct oral anticoagulants cause placental vascular abnormalities and epigenetic reprogramming in placenta and the offspring

Singh, KK

Hypercoagulability impairs plaque stability in diabetes-induced atherosclerosis

IRE1α induced senescence promote endothelial barrier dysfunction in diabetes-induced atherosclerosis

Singh, S

Low resolution cryo-EM maps and AFM analysis combined with alpha fold model of full-length coagulation Factor VIII sheds light on the conformational positioning of the Factor VIII B domain

An improved understanding of native coagulation factor XIII complex structure using cryo-EM

Analyzing secretion-based patterns of the heterozygous species of coagulation Factor XIII B cysteine mutations reported from mild FXIII deficiency using confocal microscopy

Sivamurthy, K

Durability of Factor IX activity and bleeding rate in people with severe or moderately severe haemophilia B after long-term follow-up in the phase 1/2 Study of AMT-060, and phase 2b and phase 3 studies of etranacogene dezaparvovec (AMT-061)

Slavik, L

Can APC inhibition by lupus anticoagulants indicate antibody thrombogenicity?

Slavík, L

Markers of coagulopathy in multiple myeloma

Slawka, S

Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Solari, FA

A hierarchical network of Src, Syk, Btk and PKC controls GPVI-dependent human platelet activation

Solomon, C

Phase 3 study of the efficacy, pharmacokinetics, immunogenicity and safety of von Willebrand Factor/Factor VIII concentrate in patients with severe von Willebrand Disease under 6 years of age

Somanathan, S

Global seroprevalence of neutralizing antibodies against adeno-associated virus (AAV) serotypes of relevance to gene therapy

Spannagel, U

Therapeutic interventions and use of point of care DOAC Dipstick test in stroke patients: an interim analysis of a prospective cohort study

Use of DOAC Dipstick point-of-care testing in patients with acute stroke and transient ischemic attack

Spannagl, M

The beauty of real-world data. EHL factor concentrates contribute to declining annual bleed rates

Sparber-Sauer, M

Patient-reported symptoms to predict intra-articular location of joint bleeds

Speer, P C

Ontogeny of peripheral blood platelet GPIIb/IIIa activation and granule release in preterm and term neonates

Spieth, P

Monitoring of argatroban in COVID-19 ICU patients: a prospective study comparing aPTT, point-of-care viscoelastic testing with ECA-test and dTT to LC/MS/MS

Monitoring of unfractionated heparin in critical ill ICU patients: a prospective study comparing aPTT and point-of-care viscoelastic testing with IN /HI ratio to anti-Xa

Sprinzl, M

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

Stambouli, O

Plasma-derived extracellular vesicles: a look at the preanalytics

Starostka, D

Markers of coagulopathy in multiple myeloma

Steinauer, T

Sequential combinations of rapid immunoassays for quick recognition of heparin-induced thrombocytopenia

Utility of D-dimers in the diagnostic work-up of heparin-induced thrombocytopenia (HIT)

Steiner, D

The Post-VTE Functional Status Scale for assessment of functional limitations in patients with venous thromboembolism: construct validity and responsiveness in a prospective cohort study

Characteristics, management, disposition, and outcome of patients with pulmonary embolism in a tertiary care setting

Stichel, D

Characterization of the influence of heat- and acid-treatment on the FVIII-antibody interaction in order to improve inhibitor diagnostics

Stracke, D

Pain in patients with hereditary bleeding disorders: evaluation of a survey among people affected in Germany

Strauch, K

Discriminatory potential of platelet function reference ranges in cardiovascular disease

Streif, W

Low bone mineral density in hemophiliacs: cell culture experiments to elucidate the role of coagulation factors in bone metabolism

Strini, T

Developing an assay to determine the individual osteoclastogenic potential of patients with coagulation disorders in-vitro: challenges and pitfalls

Studt, J-D

Limited concordance of heparin/PF4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study

Su, C

The effect of prophylactic corticosteroid treatment on adeno-associated virus-mediated gene therapy and potential mechanisms of action

Sulzer, I

Biobanking for testing hemostasis: Long-term stability of citrated plasma samples

Sunder-Plaßmann, R

Impaired hemostatic capacity in patients with low von Willebrand factor

Szabo, K

Use of DOAC Dipstick point-of-care testing in patients with acute stroke and transient ischemic attack

Szafranski, K

Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec (CSL222) vs. extended half-life Factor IX therapies for severe or moderately severe hemophilia B

Tahmasbi Rad, M

Investigation Of endometriosis symptoms and tumor marker CA 125 in patients With hereditary Von Willebrand disease

Tamamushi, Y

Inhibition of cold-induced apoptosis of platelet concentrates improves platelet functionality and half-life

Tarasco, E

Neonatal exchange transfusion: hereditary thrombotic thrombocytopenic purpura (hTTP) should be in the differential diagnosis

Tarrant, J

Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B

ten Cate, H

Platelet responsiveness in the post-acute phase of pulmonary embolism

ten Cate, V

Discriminatory potential of platelet function reference ranges in cardiovascular disease

Platelet responsiveness in the post-acute phase of pulmonary embolism

Teodoro, V

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Tertel, T

Plasma-derived extracellular vesicles: a look at the preanalytics

Teulon, J-M

Low resolution cryo-EM maps and AFM analysis combined with alpha fold model of full-length coagulation Factor VIII sheds light on the conformational positioning of the Factor VIII B domain

Thaler, J

Saliva and urine from persons with hemophilia A trigger coagulation bypassing factor VIII

Tissue Factor Pathway Inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer

Thiele, T

A novel, homozygous mutation in GFI1B causing inherited thrombocytopenia with Glanzmann-like platelet dysfunction

The impact of enhanced platelet turnover on platelet reactivity in healthy humans

Thomas, S

Pharmacological targeting of ACKR3/CXCR7 enhances anticoagulant acylcarnitine levels in platelets and modulates thrombotic response to lipids

Thomas, W

Efficacy, safety and consumption of plasma-derived von Willebrand factor (VWF)/Factor VIII (FVIII) concentrate with 2.4:1 VWF:FVIII ratio for the treatment of von Willebrand Disease: a systematic review

Tiebel, O

Monitoring of argatroban in COVID-19 ICU patients: a prospective study comparing aPTT, point-of-care viscoelastic testing with ECA-test and dTT to LC/MS/MS

Monitoring of unfractionated heparin in critical ill ICU patients: a prospective study comparing aPTT and point-of-care viscoelastic testing with IN /HI ratio to anti-Xa

Tiede, A

Patient-reported symptoms to predict intra-articular location of joint bleeds

Interim analysis in patients from Germany and Switzerland of the A-MORE study: a 48-month, multi-centre, observational study to evaluate longterm effectiveness of rFVIIIFc on joint health

Monitoring of emicizumab in acquired hemophilia A

Tinguely, M

Recombinant ADAMTS13 treatment in a pregnant patient with hereditary thrombotic thrombocytopenic purpura

Tittl, L

Periinterventional management of edoxaban in major procedures: results from the DRESDEN NOAC REGISTRY

Treatment of VTE with rivaroxaban in adolescents – long-term results from the prospective Dresden NOAC Registry (NCT01588119)

Tokic, S

Developing an assay to determine the individual osteoclastogenic potential of patients with coagulation disorders in-vitro: challenges and pitfalls

Tomschi, F

Insights in pain processing of affected versus non-affected structures

Structural alteration and impact on pain perception in patients with haemophilia

Trinchero, A

Conclusion from 50 years of reports on prekallikrein or high-molecular-weight kininogen deficiency

Tsakiris, DA

Limited concordance of heparin/PF4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study

Tsurkan, M

Polymer anchors with responsive heparin release for the anticoagulant decoration of hemodialysis membranes

Türkantoz, H

Monitoring of emicizumab in acquired hemophilia A

Türknetz, M

PreviouslyuntreatedpatientsinGermany2017 - 2021 – Update 2022

Udvardi, P

EMIIL - Non-interventional study to investigate the effectiveness of Emicizumab under real-world conditions in pediatric, adolescent, adult and elderly patients with hemophilia A (PwHA) with and without FVIII inhibitors: an interim analysis

Ugurlar, D

Low resolution cryo-EM maps and AFM analysis combined with alpha fold model of full-length coagulation Factor VIII sheds light on the conformational positioning of the Factor VIII B domain

Uruglar, D

An improved understanding of native coagulation factor XIII complex structure using cryo-EM

Uzun, G

Severe bleeding in a young patient with mild thrombocytopenia due to a novel mutation in growth factor inhibitor 1B

Anti-PF4 antibodies after SARS-CoV-2 vaccines: long term follow-up

Van Alphen, F

Exploring red blood cells as a novel tolerogenic approach for Factor VIII inhibitors employing immuno-dominant FVIII derived peptides presented on MHC class II

Van Bruggen, R

Exploring red blood cells as a novel tolerogenic approach for Factor VIII inhibitors employing immuno-dominant FVIII derived peptides presented on MHC class II

van der Vorst, EPC

Gut microbiota promotes arterial thrombus formation in hyperlipidemic Ldlr-/- mouse model

Vanhoorelbeke, K

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

Van Tuyl, A

Non-clinical pharmacodynamic effects and immunogenicity assessment of prophylactic immune modulation prior to gene therapy dose administration in C57BL/6 mice

Vater, L

Assessment of platelet abnormalities in patients with DiGeorge Syndrome by immunofluorescence microscopy on the blood smear

Platelet expression of the transcription factor ETV6 points toward ETV6-related thrombocytopenia and can be detected by immunofluorescence on the blood smear

Aggregates of non-muscle myosin IIA in the erythrocytes associate with GATA1-related thrombocytopenia

Platelet GPIIbIIIa enriched membrane protrusions (Tether) in healthy and diseased individuals

Ventriglia, G

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Verweij, S

Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B

Vettermann, C

Interim 52-Week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A

Veuthey, L

Identification of key regulators of procoagulant COAT platelet generation by quantitative phosphoproteomic analysis and phosphoflow

The role of Mitochondrial Calcium Uniporter in platelet signalling

In vitro efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis

Vicent, O

Monitoring of argatroban in COVID-19 ICU patients: a prospective study comparing aPTT, point-of-care viscoelastic testing with ECA-test and dTT to LC/MS/MS

Monitoring of unfractionated heparin in critical ill ICU patients: a prospective study comparing aPTT and point-of-care viscoelastic testing with IN /HI ratio to anti-Xa

Villareal Martinez, L

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Vishnu, P

Limited concordance of heparin/PF4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study

Vogler, T

Structural alteration and impact on pain perception in patients with haemophilia

Voigtländer, M

BMS-262084, a FXIa inhibitor, interferes with tumor cell-induced coagulation activation only in tumor cells with low tissue factor (TF) procoagulant activity (PCA)

von, A Drygalski

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

von, C Auer

The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura

von, K Bargen

Impaired signaling pathways in Glanzmann thrombasthenia platelets

von, S Mackensen

Assessment of health status, quality of life and physiCAL functIoninG of refUgee hemophiLia patients from UkrAine (CALIGULA Study)

von Bargen, K

Plasma-derived extracellular vesicles: a look at the preanalytics

Aspirin resistance and higher risk of pump thrombosis in patients with ventricular assist device – a 7-year follow up study

Von Depka, M Prondzinski

Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B

von Depka Prondzinski, M

HEM-POWR study: Subgroup analysis evaluating the real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Germany

von Eckardstein, A

Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer

von Krogh, A S

Neonatal exchange transfusion: hereditary thrombotic thrombocytopenic purpura (hTTP) should be in the differential diagnosis

von Ungern-Sternberg, S

Discriminatory potential of platelet function reference ranges in cardiovascular disease

Platelet responsiveness in the post-acute phase of pulmonary embolism

Voorberg, J

Exploring red blood cells as a novel tolerogenic approach for Factor VIII inhibitors employing immuno-dominant FVIII derived peptides presented on MHC class II

Vostatek, R

Telomere length is associated with increased risk of cardiovascular events in hemodialysis patients

Walter, U

A hierarchical network of Src, Syk, Btk and PKC controls GPVI-dependent human platelet activation

Wang, J-D

Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1

Wang, M

Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1

Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Wang, R

Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B

Warken, J

Second- and third-generation FVIII-specific CAR Treg responses to FVIII are functionally affected by the combination of FVIII-specific scFvs and intracellular costimulatory domains

Wasmer, S

Biallelic GNE variants in patients with congenital thrombocytopenia

Weber, A

Sensitive and unambiguous measurement of the activated contact activation factor XII

A sensitive and selective method for the measurement of activated factor X based on complex formation with tissue factor pathway inhibitor

Weber, B

The Post-VTE Functional Status Scale for assessment of functional limitations in patients with venous thromboembolism: construct validity and responsiveness in a prospective cohort study

Weiss, ACG

Understanding the biomolecular corona formation at the nano-bio interface

Weiss, C

Use of DOAC Dipstick point-of-care testing in patients with acute stroke and transient ischemic attack

Weiss, J L

Ontogeny of peripheral blood platelet GPIIb/IIIa activation and granule release in preterm and term neonates

Weiß, J L

Distinct functional defects in platelet subpopulations after hematopoietic stem cell transplantation

Weisz, T-E

Phase 3 study of the efficacy, pharmacokinetics, immunogenicity and safety of von Willebrand Factor/Factor VIII concentrate in patients with severe von Willebrand Disease under 6 years of age

Wenning, S

Real-world experience on the use of rIX-FP in patients with hemophilia B: interim results from a prospective, non-interventional study in Germany

A snapshot analysis of a prospective, non-interventional study to evaluate real-life prophylactic treatment schedules of factor VIII concentrates

HEM-POWR study: Subgroup analysis evaluating the real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Germany

EMIIL - Non-interventional study to investigate the effectiveness of Emicizumab under real-world conditions in pediatric, adolescent, adult and elderly patients with hemophilia A (PwHA) with and without FVIII inhibitors: an interim analysis

Wenzl, F

Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer

Werner, C

Polymer anchors with responsive heparin release for the anticoagulant decoration of hemodialysis membranes

Understanding the biomolecular corona formation at the nano-bio interface

Werwitzke, S

Monitoring of emicizumab in acquired hemophilia A

Wesche, J

A novel, homozygous mutation in GFI1B causing inherited thrombocytopenia with Glanzmann-like platelet dysfunction

Platelet GPIIbIIIa enriched membrane protrusions (Tether) in healthy and diseased individuals

Role of Neuraminidase A of S. pneumoniae on platelet-bacteria-interaction

Developing an assay to distinguish between HIT and VITT antibodies

Wieland, I

Assessment of platelet abnormalities in patients with DiGeorge Syndrome by immunofluorescence microscopy on the blood smear

Agenesis of vena cava inferior (AVCI) and Hypereosinophilic Syndrome (HES): two rare causes of severe thrombosis and its challenging treatment in adolescents

Wild, S P

Discriminatory potential of platelet function reference ranges in cardiovascular disease

Platelet responsiveness in the post-acute phase of pulmonary embolism

Wilgenbus, P

Immune modulation by the endothelial protein C receptor (EPCR) in cancer progression

Wilhelm, J

Diagnostic challenges of Thrombotic Thrombocytopenic Purpura: Results from a cohort of 3,100 individual patients in a time period of 21 months

Willmann, O

Use of DOAC Dipstick point-of-care testing in patients with acute stroke and transient ischemic attack

Wilson, C

Non-clinical pharmacodynamic effects and immunogenicity assessment of prophylactic immune modulation prior to gene therapy dose administration in C57BL/6 mice

Winburn, I

Global seroprevalence of neutralizing antibodies against adeno-associated virus (AAV) serotypes of relevance to gene therapy

Windisch, M

Healthcare professionals (HCPs) in Austria are positive about gene therapy, but expressed a need for a more topic related education

Windyga, J

Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Witkop, M

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Witzemann, A

Platelets are pre-activated during thrombocytopenia in a subset of early malaria infections

Establishment of an ex vivo assay to investigate thrombus formation using platelet concentrates

Wolf, M

Anti-PF4 antibodies after SARS-CoV-2 vaccines: long term follow-up

Wolff, M

Platelet GPIIbIIIa enriched membrane protrusions (Tether) in healthy and diseased individuals

The impact of enhanced platelet turnover on platelet reactivity in healthy humans

Wolny, M

Impaired signaling pathways in Glanzmann thrombasthenia platelets

Plasma-derived extracellular vesicles: a look at the preanalytics

Aspirin resistance and higher risk of pump thrombosis in patients with ventricular assist device – a 7-year follow up study

Wolter, C

Blood-induced inflammation in hemophilia

Wolz, R

Endothelial protein C receptor signaling regulates myeloid-biased hematopoiesis under stress and in aging

Wöß, C

Bridging the gap between coagulation in experimental research and clinical hemostaseology – a modified rotational thromboelastometry assay to show the pro-coagulatory effect of senescence on human blood

Wrin, T

Global seroprevalence of neutralizing antibodies against adeno-associated virus (AAV) serotypes of relevance to gene therapy

Wuillemin, W

Limited concordance of heparin/PF4 antibody assays for the diagnosis of heparin-induced thrombocytopenia: an analysis of the TORADI-HIT study

Wurmbäck, P

The impact of Syk-inhibition on 5B9 monoclonal HIT antibody-mediated procoagulant platelet formation

Wüst, F

The beauty of real-world data. EHL factor concentrates contribute to declining annual bleed rates

Xie, L

The effect of prophylactic corticosteroid treatment on adeno-associated virus-mediated gene therapy and potential mechanisms of action

Yadegari, H

Investigating the interaction of circulating von Willebrand factor with polymorphonuclear leukocytes ex vivo

Yan, S

Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec (CSL222) vs. extended half-life Factor IX therapies for severe or moderately severe hemophilia B

Yates, B

The effect of prophylactic corticosteroid treatment on adeno-associated virus-mediated gene therapy and potential mechanisms of action

Young, G

Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Yu, H

Interim 52-Week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A

Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

Yu, Y

Bridging the gap between coagulation in experimental research and clinical hemostaseology – a modified rotational thromboelastometry assay to show the pro-coagulatory effect of senescence on human blood

Zakariah, Nurzazlin Nazatul

Comparative transcriptome profile analysis on early T2DM-aggravated atherosclerotic mouse aortas

Zaninetti, C

Assessment of platelet abnormalities in patients with DiGeorge Syndrome by immunofluorescence microscopy on the blood smear

Platelet expression of the transcription factor ETV6 points toward ETV6-related thrombocytopenia and can be detected by immunofluorescence on the blood smear

A novel, homozygous mutation in GFI1B causing inherited thrombocytopenia with Glanzmann-like platelet dysfunction

Aggregates of non-muscle myosin IIA in the erythrocytes associate with GATA1-related thrombocytopenia

Platelet GPIIbIIIa enriched membrane protrusions (Tether) in healthy and diseased individuals

Zermatten, G M

Emicizumab phamacodynamics assessed by thrombin generation and fibrin clot formation

Evaluating the individual risk of venous thrombo-embolism in patients with liver cirrhosis: Usefulness of in vivo and ex vivo thrombin generation parameters

Zermatten, MG

In vitro efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis

Zhang, L

The effect of prophylactic corticosteroid treatment on adeno-associated virus-mediated gene therapy and potential mechanisms of action

Zhang, P

A hierarchical network of Src, Syk, Btk and PKC controls GPVI-dependent human platelet activation

Zhang, X

Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec (CSL222) vs. extended half-life Factor IX therapies for severe or moderately severe hemophilia B

Zieger, B

Inherited platelet disorders – a short introduction

PreviouslyuntreatedpatientsinGermany2017 - 2021 – Update 2022

Biallelic GNE variants in patients with congenital thrombocytopenia

Current diagnostic and therapeutic standard of iliac vein compression syndrome (May-Thurner syndrome) in children, adolescents and young adults. A survey among national thrombosis experts

Developing an assay to determine the individual osteoclastogenic potential of patients with coagulation disorders in-vitro: challenges and pitfalls

Ziegler, M

Use of DOAC Dipstick point-of-care testing in patients with acute stroke and transient ischemic attack

Zierk, J

Patient-reported symptoms to predict intra-articular location of joint bleeds

Zimmerman, R

Genetic background of von Willebrand disease

Zimmermann, S

Platelet hyperactivation and neutrophil extracellular traps promote thrombo-inflammation and glomerular endothelial dysfunction in diabetic kidney disease

Zlamal, J

The impact of Syk-inhibition on 5B9 monoclonal HIT antibody-mediated procoagulant platelet formation

Establishment of an in vitro assay to detect antibody-mediated procoagulant platelet formation on a single cell level in real time

Measurement of procoagulant platelets in platelet-rich plasma by flow cytometer for the diagnosis of heparin-induced thrombocytopenia

Úlehlová, J

Markers of coagulopathy in multiple myeloma

Can APC inhibition by lupus anticoagulants indicate antibody thrombogenicity?